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The two primary means by which alternative medical or surgical treatments
are assessed is through the use of randomized controlled trials (RCTs) or
observational studies (OS) (Hannan 2008). In RCTs, participants are ran-
domly assigned to a treatment or control group (or to multiple treatment
groups) so as to reduce bias by making the groups as equal as possible with
respect to all patient characteristics that may have an impact on outcomes.
Thus, in theory, the only diﬀerence between the groups is the treatment
assignment and any diﬀerences that are identiﬁed. In contrast, OS do not
randomize treatment but ‘observe’ diﬀerences in outcomes that occur after
treatment decisions have been made, without regard to ensuring that patients
in diﬀerent treatment arms have similar characteristic related to outcomes.
Treatments may be diagnostic, preventive or therapeutic and may include
drugs, biologics, medical advices or methods of screenings. Treatments may
also include procedures whose aim is to improve quality of life or to bet-
ter understand how the intervention works in partecipants (Peace and Chen
2011).
Clinical trials and observational studies usually generate both longitudi-
nal measurement data, with repeated measurements of one or more response
variables at a number of time points for each participant, and event his-
tory data, in which times to recurrence or terminating events are recorded
(Henderson et al. 2000). A widely used example is in AIDS research where
a biomarker called CD4 lymphocyte count is measured intermittently and
both its progression and relationship with time to seroconversion or death
Iis of interest (e.g. DeGruttola et alt., 1993; Tsiatis et al., 1995; Wulfsohn
and Tsiatis, 1997). Another example comes from studies following men who
have been treated with deﬁnitive local therapy (i.e. radical prostatectomy
or radiation therapy) for localized prostate cancer. Despite the shift to ear-
lier treatment due to a recent widespread use of early detection programs, a
substantial percentage of these patients shows evidence of biochemical recur-
rence within 10 years after treatment (Taylor et al., 2005). Prostate-speciﬁc
antigen (PSA) is the covariate commonly used to monitor patients after they
have been treated. In fact, several studies have shown that a rise of post-
treatment PSA is highly predictive of clinical recurrence (Ali et al. 2006).
Thus, at the end of studies similar to those described above, we often
have the following situations (Wu 2010):
• “the main focus is on modeling the survival data, with modeling lon-
gitudinal data being secondary”. For example, our attention is direct
to the event outcome and we wish to account for the eﬀect of the lon-
gitudinal outcome as a time-dependent covariate.
• “the main focus is on modeling longitudinal data, with modeling sur-
vival being secondary”. We could be in this situation when we analyze
longitudinal data where dropouts are informative so that the survival
data could be only used to account for the informative dropouts.
• “the main focus is on modeling both the longitudinal data and the sur-
vival data, with goal of understanding the association between the two
processes”. This situation arises, for instance, when we wish to charac-
terize the relationship between features of a time-dependent covariate’s
trajectory and the survival endpoint in order to assess the prognostic
value of the longitudinal covariate and, in presence of treatment, to
verify the possibility to use it as a ‘surrogate marker’ (Fitzmaurice et
al. 2008).
In all three situations, traditional approaches used to analyze survival or lon-
gitudinal data are not applicable without incurring in biased results. Taking
IIin consideration the ﬁrst situation, several problems are present. First, stan-
dard time-to-event models (e.g. proportional hazard models (Cox 1972))
require that time-dependent covariates are external: although the value of
this covariate at time point u “inﬂuence the rate of failures over time, its
future path up to time t > u is not aﬀected by the occurrence of a failure
at time u” (Kalbﬂeisch and Prentice 2002, Section 6.3). However, most of
the time-dependent variables observed in longitudinal studies are internal so
that they do not satisfy this condition. Internal variables, in fact, are usu-
ally the output of a stochastic process generated by the subject under study.
Consequently, they are only observed as long as the subject is alive and un-
censored and therefore they implicitly carry information about the failure
time. Second, to apply Cox’s methods for the estimation of the model pa-
rameters, it is necessary to have complete knowledge of the covariate history
for all individuals while on study (Tsiatis 1995). In most studies, however,
the time-dependent covariate is collected only intermittently on each indi-
vidual during medical examinations whose frequency can change from once
a day to once a year according to the study protocol. Third, to optimally
estimate the parameter models, we would need to know the covariate value
without measurement error (Wulfsohn and Tsiatis 1997). Prentice (1982)
established that the presence of the measurement error (i.e. a random error)
in a measured covariate causes the estimated parameters to be biased to-
wards the null. Also Tsiatis (1995) stressed that the maximum explanatory
power of the time-dependent covariate on the hazard can only be achieved
after adjustment of measurement error. Using the observed value, the pos-
sible relationship between the covariate and the time-to-event or between
the covariate and the treatment eﬀect could not be detected. In the second
situation there is the need to deal with informative dropout. Dropout hap-
pens when, during the follow-up, a subject ‘drops out’ or is withdraw from
the study before the study is completed. The dropout mechanism is said to
be informative when the probability of dropout is related to speciﬁc values
that should have been obtained, have the subject not left the study. If an
IIIanalysis is conducted without taking informative dropout into account, its
results could be potentially biased. Obviously, the third situation presents
all those problems together.
In order to avoid all these problems and obtain valid inferences, joint
models for longitudinal and survival data have been proposed. Wulfsohn
and Tsiatis (1997) develop a methodology whereby a joint maximization of
the likelihood from both the covariate process and the survival data occurs.
In particular, their method uses not only the observed covariate data but
also survival information to estimate the true covariate value at any time.
Therefore the authors expects more precise and accurate estimates of the
strength of the relationship between the covariate risk and the risk of failure
than those obtained from previous methods such as the ‘Last value of Last
Observation Carried Forward’ or the ‘Two-Step’ approach.
In the last decade, joint models have been mainly applied in medical
studies to correctly estimate the association between a time-dependent co-
variate, usually a biomarker, and baseline covariates with the event outcome,
verifying candidate risk factors and testing treatments’ eﬀect in prolonging
survival. A biomarker indicates a change in expression or state of a biological
measurement (e.g. concentration of a protein or an antigen in serum or other
tissues, aneurysm diameter, blood pressure, ...) at a given time point. A
biomarker, if validated, could be used as a surrogate for subsequent survival.
Buyse et al. (2000) distinguish two diﬀerent types of surrogacy: trial-level
and individual-level surrogacy. The trial-level surrogacy coincides with the
surrogacy also described by Prentice (1989). He deﬁnes a surrogate endpoint
to be “a response variable for which a test of the null hypothesis of no re-
lationship to the treatment groups under comparison is also a valid test of
the corresponding null hypothesis based on the true endpoint”. This means
that a biomarker that is inﬂuenced by the tested treatment if and only if the
treatment has a signiﬁcant eﬀect on survival is a good surrogate endpoint.
On the other hand, at the individual level, a biomarker would be a useful
surrogate endpoint if the trajectory of irregularly observed values available
IVat any time for a single subject provides helpful prognostic information on
subsequent survival of that subject (Henderson et al. 2000).
Indeed, one aspect of joint models that has recently gained some increas-
ing interest is to obtain subject-speciﬁc predictions for either the longitu-
dinal or survival outcomes (Sweeting and Thompson 2011, Yu and Taylor
2008, Proust-lima and Taylor 2009). The ability of incorporating the whole
biomarker’s trajectory over time gives to joint models the possibility to pro-
duce dynamic prognostic tools that could more accurately guide clinical de-
cision making. For example, the complete post-treatment PSA pattern of
a patient can be used to predict the probability of biochemical recurrence
within two years from the last visit time. If the PSA pattern is suggestive of
an increase risk of clinical recurrence, the physician may decide to put the
patient on hormone therapy to slow progression of the disease or to perform
a prostatectomy.
The aim of this thesis is to compare the predicted individual survival
probabilities estimated by models where diﬀerent types of association be-
tween the longitudinal biomarker and the survival outcome are considered.
In fact, although it is often assumed that the risk for an event at a partic-
ular time point t depends on the true level of the longitudinal marker at
the same time point, it is not realistic to expect that this parameterization
will always be the most appropriate in expressing the correct relationship
between the two processes. This is in line with the more challenging nature
of time-dependent covariates with respect to baseline covariates. Since the
true functional form of a time-dependent covariate is often not self-evident
and that the choice of how to model it can considerably inﬂuence the derived
results, the researcher should not always rely on the standard formulation but
rather prudently face the problem and investigate diﬀerent parameterizations
and possibly their combinations. In addition to what just said, Henderson
(2002) also found that diﬀerent models, even if they ﬁt average characteristics
equally well, may give quite diﬀerent predictions for individual patients.
In Chapter 1 we will underline the importance of prognosis in everyday
Vmedical practice and the necessity of having accurate survival predictions
in order to properly program patients’ therapy. Moreover we will show how
some selected biomarkers could be used to increase the precision of prognosis.
In Chapter 2 we will describe the traditional approach used to analysis
survival data where time-dependent covariates are involved and we will point
out the problems arising from such approach. Thus, in Chapter 3, we will
present the joint model approach which solves, or at least greatly reduce,
those problems.
In Chapter 4 we will present how survival predictions can be computed
within the joint modeling framework and we will indicate the diﬀerent asso-
ciation structures which could be used as an alternative to the usual one.
In Chapter 5 we will show how the use of diﬀerent association structures
can substantially inﬂuence survival predictions. In our analysis we used a
dataset based on a clinical trial involving subjects aﬀected by primary biliary
cirrhosis (PBC).
VIChapter 1
Prognostic models in medicine
1.1 The meaning of prognosis
The word prognosis comes from the Greek πρ´ oγνωσις. It is composed by the
preﬁx πρo- (“before”) + γν˜ ωσις (gnosis, “inquiry, investigation, knowing”).
Thus literary it means “to know beforehand” or, as a noun, foreknowledge.
Prognosis is the prediction of what is judged likely to happen in the future,
especially in connection with a particular situation and relative to the infor-
mation available at the time of prediction.
A ﬁeld where prognostication is a daily practice is medicine. According to
Abu-Hanna and Lucas (2001), medical prognosis is deﬁned as “the prediction
of the future course and outcome of disease processes, which may either con-
cern their natural course or their outcome after treatment”. Thus a prognosis
is made every time a patient is diagnosed with a disease and its importance
increases whether the disease can lead to a signiﬁcant decrement in the pa-
tient’s quality of life or to death. Indeed, physicians specialized in cardiology,
neurology, intensive care medicine and oncology, from newly diagnosed to ter-
minally ill patients, are especially required to be able to prognosticate and
this does not only imply making survival predictions. Physicians are required
to be able to indicate disease evolution, possible disabilities that the patient
would be facing, response and side eﬀects associated with diﬀerent treatment
1options and, eventually, costs of health care (Glare et al. 2008). Prognosis
is interlaced with other tasks of clinical management of the patient such as
diagnosis, therapy selection and planning. Information obtained at diagno-
sis and knowledge about feasible medical actions, with therapy in the ﬁrst
place, have a strong inﬂuence on prognosis. Therefore, prognosis could be
considered a comprehensive decision tool that, according to all the informa-
tion available at the time of diagnosis, allows clinicians to choose the most
appropriate way to tackle the speciﬁc disease.
From now on, the aspect of prognosis that will be considered is the pre-
diction of survival time, in the sense of time elapsed before disease recurrence
or death.
Since prognosis has such a deep inﬂuence on patients’ future, it is uni-
versally recognized that prognosis has to be as much accurate as possible.
For cancer patients, for example, Mackillop and Quirt (1997) individuated
three reasons why accurate predictions are required. These reasons can eas-
ily be generalized to other types of disease. First, physician’s prognosis has
an inﬂuence in the choice of treatment. The probability of cure associated
with each potential treatment and the patient’s expected survival have to be
carefully assessed since many cancer treatments (e.g. biological therapy, ra-
diation therapy, chemiotherapy, ...) have important side-eﬀects which may
initially decrease the quality of life and may only be considered acceptable if
the patient is likely to live long enough to experience any subsequent treat-
ment’s beneﬁt. Patients with an incurable cancer or at the latest stages
should be advised on palliative care programs. Second, accurate prognostic
judgment contributes to the eﬃcient use of health care resources since treat-
ing patients with expensive therapies that will not give any beneﬁt not only
submits the patient to useless toxicity, but also waste important resources
that could be spent elsewhere. Third, good predictions may help patients
and their families to make appropriate plans for the remaining time in order
to take advantage of every day.
Also national and local Health Authorities are particularly interested in
2the fact that survival predictions are as much accurate as possible since
patients may qualify for speciﬁc ﬁnancial beneﬁts if their life expectancy is
below a speciﬁed threshold. For instance, Henderson et al. (2001) refer that
“in U.K., a patient can claim additional ﬁnancial support without the usual
waiting time if a doctor certiﬁes that the patient has ‘progressive disease’
and it is not expected to live longer than six months”. In the U.S.A., the
Medicare insurance programme1 introduced hospice care for its beneﬁciaries.
In order to be eligible for Medicare hospice beneﬁts, the patient’s doctor and
the hospice medical director have to certify that the patient is terminally
ill and probably have less than six months to live (Medicare). These two
examples are enough to further underline the importance of giving accurate
prognosis, both for patients’ interest and health programs’ eﬃciency.
1.2 Accuracy in survival predictions
In most of the cases, patients diagnosed with life-threatening diseases want
a high level prognostic information. A study involving 126 patients with in-
curable metastatic cancer found that 95% of them wanted information about
side eﬀects, symptoms, and treatment options and the 98% indicated that
the doctor should be realistic, provide an opportunity to ask questions, and
acknowledge the patient as an individual when discussing prognosis (Hagerty
et al. 2005). Although patients clearly want prognostic information, doctors
feel this task stressful and diﬃcult. Christakis and Iwashyna (1998) in a
study involving 697 American internists investigating attitude and practice
about prognostication found that doctors “believed that patients expect too
much certainty and that both patients and (to a lesser extent) colleagues will
judge them adversely for prognostic errors”. Those doctors believed also that
1Medicare is a social insurance program administered by the United States govern-
ment (CMS), providing health insurance coverage to people who are aged 65 and over; to
those who are under 65 and are permanently physically disabled or who have a congen-
ital physical disability; or to those who meet other special criteria such as terminally ill
patients.
3“they should accentuate the positive in making predictions and avoid being
too speciﬁc” and that it is better not to volunteer prognostic assessments.
One of the possible reasons that make clinicians so uncomfortable when they
are asked for a prognosis is the intrinsic uncertainty that characterizes the
course of the disease. The probability of error will never be completely re-
moved when predicting future outcomes, especially when considering the
complex dynamic of the human body and the multiple interactions between
the human body and illness (Glarea et al. 2008). Nevertheless, the im-
possibility to formulate 100% accurate prognosis does not have to stop the
research of tools that could improve clinicians’ prognostications.
The two approaches used in order to formulate the prognosis are: clinical
prediction of survival (CPS) and use of statistical tools such as prognostic
models. CPS is a procedure in which the judge puts clinical data together
using informal, subjective methods. Thus, CPS is essentially based upon
physicians’ experience. Even though, as it has been said before, prognosis,
and hence CPS, does have a decisive impact on many aspects, the studies
assessing accuracy in physicians’ survival predictions are few and most of
them are based on data from terminally ill patients. It is not easy to com-
pare the results from these studies since there is not a worldwide deﬁnition of
prediction accuracy. Nevertheless, in most of the cases, the conclusions are
the same. Probably, the very ﬁrst study about this subject was published by
Parkes in 1972. The research was conducted in a hospice in Sydenham (close
to London) where the author asked general practitioners or hospital medical
staﬀ to state the expectation of life in weeks for all those patients with a
diagnosis of cancer who were admitted to the hospice during 1970-1. At the
end of the study, there were 293 predictions of survival made on 168 cancer
patients. In order to analyse the data, Parkes used his own deﬁnition of
accuracy: prediction is in ‘serious error’ if it diﬀers from the actual survival
(AS) by a multiplicative factor of two, that is, if AS>2CPS or AS<0.5CPS.
Using this criterion, overall the rate of error was 53% with a 83% of them in
an optimistic direction. More recently, Christakis and Lamont (2000) con-
4ducted a large, prospective cohort study of terminally ill patients to evaluate
the extent and determinants of prognostic error. In the end, the study had
information from 343 physicians caring for 468 patients and both CPS and
AS were made in days. In order to verify prognostic error, the authors “di-
vided the observed by the predicted survival and deemed prognoses accurate
if this quotient was between 0.67 and 1.33”. Hence, CPSs’ values with quo-
tients between 0.67 and 1.33 times the AS were accurate, values less than
0.67 were optimistic prognostic errors, and values greater than 1.33 were pes-
simistic. The authors found that 92 (19.7%) of 468 predictions were accurate,
295 (63.0%) were optimistic, and 81 (17.3%) were pessimistic. Whereas us-
ing Parker’s deﬁnition of prognostic error, 159 (34.0%) of 468 predictions
were accurate, 256 (54.7%) were optimistic, and 53 (11.3%) were pessimistic.
Moreover, the authors reported that “physicians in the upper quartile of
practice experience were the most accurate” and that “as the duration of the
doctor-patient relationship increased and time since last contact decreased,
prognostic accuracy decreased”.
Given the importance of accurate prediction and the evidence that CPS
is a not so precise tool in this sense, an interesting question arises as to
whether the use of objective methods based on statistical models can replace
or inform subjective clinical judgment. Survival analysis is a widespread
tool used to determine covariate eﬀects, to compare diﬀerent groups (e.g.
treatment groups), and to form prognostic indices. However, as Henderson
et al. (2000) states, these models are not often used to make individual
point or interval lifetime predictions. They claim that a possible answer “is
that statistical methods have not convincingly been demonstrated to lead
to accurate and thus helpful predictions”. Indeed their study showed that
the point predictions from four diﬀerent survival models were generally quite
similar. Moreover, for all models and all individuals the probability of being
in ‘serious error’ using Parker’s criterion was around 50%.
The studies presented so far were all based on point predictions. There-
fore, it may seem appropriate to present some type of reliability measure
5as well. One option is represented by predictive intervals (Henderson and
Keideng, 2005). Predictive intervals can be obtained from survival curves,
and they give to each patient a range of outcomes within which AS will lie
with a speciﬁed probability. Nevertheless, the authors correctly recall that,
although interval estimates accurately quantify the uncertainty in prognosis,
intervals are often as wide as to be of little practical use.
In conclusion, multivariate regression models, such as survival models,
have been proven to be good tools in individuating risk factors and in com-
paring groups of patients. In particular, they are often used in distinguishing
patients with a high risk from patients with a moderate or low risk. Moreover,
even though physician’s prognostic estimates are not accurate enough to be
reliable at the patient level, they still provide valuable prognostic information
that can be used to improve statistical models. Muers et al. (1996), in a study
of advanced non-small-lung cancer patients, found that the Cox’s propor-
tional hazard model incorporating, among prognostic factors, the physician’s
point prediction of survival, was the best model discriminating between poor
and moderate/good prognosis groups. This improvement made the authors
suggest that physicians not necessarily use the same information included
in the model to predict survival and thus they might be using additional
elements on which to base their prognostic judgement. Notwithstanding the
great usefulness these models have at the population level (e.g. knowing the
modiﬁable risk factors linked to cardiovascular pathologies such as hyperten-
sion, diabetes, obesity and smoke, governments can promote health programs
with the aim of reducing the exposition of those risk factors and thus the
incidence of such diseases), their prediction ability at the patient level is,
in most of the cases, useless. The main point that Henderson and Keideng
(2005) wanted to underline with their work was that “in all realistic scenarios
we can imagine, the intrinsic statistical variations in life times are so large
that predictions based on statistical models and indices are of little use for
individual patients. This applies even when the prognostic model is known
to be true and there is no statistical uncertainty in parameter estimation”.
6The fact that both physicians and prognostic models are not able to give
accurate individual point prognosis, certainly will not stop patients from
asking “How long do I have, doctor?”. If clinicians do not want to base
their answer only on their subjective judgment, the only alternative is to
rely on epidemiological results. Nonetheless, as indicated by Scuchter (1996)
and Hollnagel (1999), the physician must carefully distinguish prediction of
the outcome for a population of patients from that for a singular patient.
In particular, Hollnagel highlights two important points which any clinician
should be aware of. “The ﬁrst is that epidemiological research can only
incorporate factors which can be measured quantitatively”. For example,
patients’ important features such as life experience, lifestyle, physical capa-
bilities, hopes and fears about the future and, even more, attitude matter
so much (Gould, 1986). But, as these factors are not usually measured and
not easily amenable to epidemiological analyses, they are largely ignored and
thus results do not account for them. “Second, epidemiological knowledge
about risk factors is group-based as opposed to individualised knowledge”.
This is a cornerstone issue that has to be tackled by every physician when
he/she is in the consulting room with a patient. The physician could be
able to assign the patient to the correct risk group and thus inform him/her
about the median survival time, treatment eﬃcacy and so on. Nevertheless,
since the variability between patients belonging to the same risk group is
often not null, the possibility that this patient would behave in a diﬀerent
way should not be ignored. Mackillop (2006), in his paper The importance
of prognosis in cancer medicine states that, in the future, “the challenge will
be to increase the ‘particularizability’ of medical knowledge in such a way
that the individual characteristics of the patient and the tumor are appro-
priately factored into treatment decisions. This will require characterizing
patients, not only in terms of the diagnostic group to which they belong,
but also in terms of all those individual characteristics that may inﬂuence
the outcome of treatment”. This sentence is referred to prognosis in oncol-
ogy but it is undoubtedly valid in other medical branches where accurate
7individualised prognosis are fundamental in supporting both physicians’ and
patients’ decision making.
Returning to the point prediction issue, what has emerged so far is opti-
mally summarized by Schumacher et al. (2003). Examining the diﬃculties
with the use of point predictions, the authors pointed out two key features.
First, the duration of survival or time to the event of interest itself cannot
be predicted adequately. Second, there seems to be no widely agreed statis-
tical methodology to assess the accuracy of predictions derived from expert
opinion or from a survival model. Consequentely, the authors suggest to
abandon predictions on the time axis and to consider only predictions on the
probability axis. Although Henderson et al. (2000) argues that the time axis
is the most natural measure, statements like ‘the chance of surviving 5 years
is 70%’ seem to be quite understandable and reveal the uncertainty about
the exact moment of death. Second, the commonly used survival models
allow to obtain individual survival probability curves which can be used as
predictions. Such curves could provide conﬁdence intervals to account for un-
certainty as well. Moreover, physicians could ﬁnd easier to make predictions
on the probability axis and give more accurate judgments. Indeed, Weeks
et al. (1998) found that physicians’ estimates of 6-year survival of cancer
patients was not so poor. For example, among patients with more than 90%
probability of surviving 6 months, 71% (41 patients over 58) actually sur-
vived, while among those with a less than 10% probability, only 11% (17
patients over 158) survived.
Albeit probabilistic predictions have been found to be more accurate than
temporal predictions, it has to be noted that they are not immune from uncer-
tainty (e.g. conﬁdence intervals of individual survival curves can be so wide
to make probabilistic predictions pointless). Traditionally, statistical survival
models used prognostic factors such as performance status, symptoms and
simple laboratory results. Even though they are often highly statistically
signiﬁcant prognostic factors, they might explain a small fraction of the vari-
ation between individuals. Thus, in the recent years, the research’s attention
8has been directed to the discovery of new prognostic factors, strongly linked
to disease progression and/or outcome, easily measurable with non-invasive
techniques, and that may be of help to clinicians for more individualised
prognosis. Easily measurable prognostic factors would also respond to the
necessity of having constantly updated prognosis. Glare et al. (2008) specify
that “prognosis is often misunderstood as a static phenomenon, reinforced
by the research studies focusing on one point in time (e.g. survival after
admission to hospital or referral to hospice, survival after the surgery, etc).
The illness trajectory changes over time, so that, as the illness evolves, new
issues must be considered and the prognosis should be revised”.
1.3 Biomarkers
From Section 1.2 it can be inferred that there is an increasing interest in
variables that could be used alone, or in more complex statistical models, in
order to provide objective information to be used by clinicians in deciding
which treatment would be better for the individual patient. Indeed, decision
making would be a lot easier if speciﬁc measurements of the patients’ clinical
status could predict the risk of progression to death. This necessity made
research to focus its attention on biomarkers. In 2001, a working group, be-
longing to the National Institute of Health, gave this standardized deﬁnition
of biomarker (NIH Deﬁnitions Working Group, 2001): “a characteristic that
is objectively measured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention”. According to this deﬁnition, a biomarker may be measured
on a biosample (e.g. blood, urine, sample of tissue), it may be measured
directly from a person (e.g. blood pressure, electrocardiogram, spirometry),
or it may be an imaging test (computed tomography, ecography, magnetic
resonance spectroscopy) (Vasan 2006).
Biomarkers can be involved in several clinical activities whose aim is to
assess patients’ health or disease characteristics. According to their applica-
9tion, biomarkers can be classiﬁed as follow (Vasan 2006):
• antecedent biomarkers: they identify the risk of developing an illness;
usually they are genetic markers that can indicate the genetic predispo-
sition of an individual to develop a speciﬁc disease. An example comes
from the Huntington’s disease, “a neurodegenerative genetic disorder
that aﬀects muscle coordination and leads to cognitive decline and de-
mentia. The disease is caused by an autosomal dominant mutation in
either of an individual’s two copies of a gene called Huntington, which
means any child of an aﬀected parent has a 50% risk of inheriting the
disease” (Wikipedia 2012). Since genetic test can be performed even
before the symptoms’ onset, a person can know in advance if he/she
will develop the disease in the future;
• screening biomarkers: they are biomarkers that indicate the presence
of a disease in asymptomatic people. For instance, the prostate-speciﬁc
antigen is a biomarker for prostate cancer used in prostate cancer
screening in an attempt to identify individuals at the early stages of
the disease;
• diagnostic markers: they are used to conﬁrm the presence of the dis-
ease among symptomatic people. An example is given by the celiac
disease. It can be diagnosed in individuals having sign or symptoms of
malabsorption or malnutrition. However, since other diseases manifest
the same symptoms, it is important to conﬁrm the disease with speciﬁc
tests: small intestinal biopsy and antibody tests are suggested;
• staging biomarkers: they are used to characterized disease severity;
• prognostic biomarkers: they are useful in predicting disease progression,
including recurrence and response to therapy. They are also used in
monitoring eﬃcacy of therapy. For example, PSA is used to monitor
biological recurrence in prostate cancer patients after radiation therapy
or radical prostatectomy while serum bilirubin level is used to monitor
10disease progression in patients aﬀected by primary biliary cirrhosis. An
example of biomarkers used to predict treatment eﬃcacy are genetic
mutations that cause drug resistance in cancer patients. From the
analysis of cancer tissue, genetic mutations, that cause speciﬁc drugs
to be ineﬀective, can be found. Consequently, the physician will have
to choose other drugs, if possible, in order to ﬁght the cancer.
It is important to notice that the same biomarker can be used with diﬀerent
purposes. PSA gives a clear example: it can be a screening, diagnostic or
prognostic biomarker.
Biomarkers may also serve as surrogate endpoints. A surrogate endpoint
is a biomarker that is used instead of the clinical endpoint (e.g. death,
biochemical recurrence, stroke or other speciﬁc events of interest) to evaluate
safety and eﬀectiveness of new treatments in clinical trials. In a seminal work,
Prentice (1989) gave the guidelines for studying surrogate endpoints and a
formal deﬁnition of conditions that the biomarker should satisfy to be used
as a valid surrogate endpoint in a speciﬁc trial. More speciﬁcally, the three
conditions where the following (Tsiatis 1995, Taylor 2002):
1. The biomarker should be associated to the clinical endpoint;
2. The treatment should have an eﬀect on the biomarker;
3. The eﬀects of the treatment should be mediated though its eﬀect on the
marker. That is, patients with the same value of the biomarker should
have the same survival probability, independently of the treatment they
are receiving.
The great attention shown in surrogate endpoints is due to several features
which they usually possess. First, candidate surrogate points are cheaper and
easier to measure than clinical endpoint. As Aronson et al. (2005) state “it
is easier to measure a patient’s blood pressure than to use echocardiography
to measure left ventricular function, and it is much easier to do echocardio-
graphy than to measure morbidity and mortality from hypertension in the
11long term”. Second, they can be measured more quickly and earlier. In fact,
blood pressure can be measured every day, whereas it usually takes several
years to collect mortality data. Third, surrogate endpoints need smaller sam-
ple sizes and can avoid ethical problems associated with measuring clinical
endpoints (Aronson et al. 2005).
However, surrogate endpoints come with disadvantages as well. In prac-
tice, it is rare to ﬁnd biomarkers satisfying all Prentice’s three conditions.
The main reason is that it is diﬃcult for a single biomarker to completely
account for all treatment eﬀects and often it is not reasonable to think that
the clinical outcome of interest is inﬂuenced by that biomarker only. That is
why, recently, some studies have focused their attention on multiple biomark-
ers that could capture various components of complex disease evolutions thus
giving a more comprehensive assessment of treatment eﬀect (NHI 2001). For
example, a recent study tested the use of multiple biomarkers to improve the
prediction of death from cardiovascular disease (Zethelius et al. 2008). The
authors concluded that “the incorporation of a combination of biomarkers
that reﬂect myocardial cell damage, ventricular function, renal function, and
inﬂammation to a model with established risk factors improved the risk strat-
iﬁcation for death from cardiovascular causes”. Another study reviewed by
many researches focused on the simultaneous examination of multiple mark-
ers in order to increase the sensitivity of the screening test for early detection
of ovarian cancer (Yurkovetsky et al. 2006). The authors concluded that “a
multimarker approach for the generation of a prototype assay for early de-
tection of ovarian cancer has a great potential to lead to the development of
a screening test for this disease”.
Regardless of the purpose of its use, a new biomarker will be of clinical
value only if it is strongly associated with the outcome of interest, it can easily
be obtained (i.e. with no harm for the patient), it has a clear interpretation
for the clinicians, it explains, despite the presence of already established risk
factors, a reasonable proportion of the outcome variability when tested in
several studies, and least, but not last, the information based on its knowledge
12have a direct impact in patient’s management.
1.4 The use of biomarkers as predictors
In this section, prostate-speciﬁc antigen (PSA) will be used to show its poten-
tiality for individualised predictions of disease progression following therapy
(i.e. radical prostatectomy or radiation therapy) for localized prostate cancer.
Then, the statistical techniques used for the analysis of similar biomarkers
will be mentioned. A more exhaustive description will be given in Chapter
3.
Patients treated for prostate cancer are usually followed for several years
in order to monitor their response to the treatment. Every patient is asked
to do medical check-ups every few months and at each visit a blood test is
performed in order to measure PSA levels. In fact, usually, after prostate
removal surgery, PSA level in the blood decreases and it eventually becomes
almost undetectable. After radiation therapy, PSA levels usually drop to
a stable and low level (WebMD). The correlation between changes in PSA
with time and prostate biochemical recurrence (i.e. local recurrence or dis-
tant metastases) has been long recognised (Oesterling 1991). However, a
widely accepted deﬁnition of biochemical recurrence based on a series of PSA
measurements has been a problematic and controversial topic. For instance,
there is considerable variability in the amount by which PSA is reduced by
radiation therapy, and the time interval before it starts to rise, if it does rise,
and the rate at which it rises are very diverse (Zagars and Pollack 1993).
Carter and Pearson in 1993 suggested to use PSA velocity, and, in particu-
lar, PSA doubling time, to identify men with prostate cancer that is destined
to progress. Pollack et al. (1994) conducted a study on patients showing a
rising PSA proﬁle after radiation therapy and they conﬁrmed PSA doubling
time (PSADT) as a strong prognostic factor for patient with biological re-
currence. They also found that “the timing of the progression from a rising
PSA to clinical disease relapse [...] is estimated to be 40 months on average”.
13This means that when a rapid increase of PSA levels is detected, there is still
time for the physician to choose a proper treatment.
Since detecting early signs of a recurrence is of major importance for pa-
tient’s care and may guide the physician’s decision to start further therapies,
such as salvage androgen deprivation therapy, it is important to be able to use
all the available information from PSA monitoring after treatment. In fact,
it is believed that methods based on the pathway of prognostic biomarkers
such as PSA could enhance their prognostic ability, hopefully giving more ac-
curate survival probabilities at the individual level. Moreover, those models
should allow to update their survival predictions after each new measurement
of the biomarker reﬂecting, in this way, the dynamic nature of disease.
The methods that were able to answer all the needs described above,
and solve all the problems arising from dealing with internal time-dependent
covariates characterized by a great variability, are known as joint models.
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Handling time-dependent
covariates
2.1 Introduction
Longitudinal studies such as clinical trials or observational studies often
record two diﬀerent kinds of data from each individual: a longitudinal se-
quence of repeated measurements at pre-speciﬁed measurement times and
one or more time-to event outcomes such as death, development of a dis-
ease, clinical recurrence or dropout from the study. Two typical examples
of this setting are HIV and cancer studies. In HIV studies, measures of im-
munological and virological status, such as CD4 T-cell count and viral RNA
copy number (also known as viral load) are gathered longitudinally on each
individual along with time to progression to AIDS or death. Likewise, in can-
cer studies, the event of interest is death or cancer recurrence and patients
provide longitudinal measurements of antibody levels or of other biomarkers
of carcinogenesis, such as PSA levels for prostate cancer, during follow-up
visits. Obviously, also several time-independent covariates, which are often
referred to as baseline covariates, are recorded, usually at the beginning of
the study.
With these types of data available, a variety of questions may be of in-
15terest, depending on the application. According to the research’s interest,
three types of setting can be deﬁned:
1. The interest could be on the event outcome and we wish to account for
the eﬀect of the longitudinal outcome as a time-dependent covariate.
In Chapter 1 it has been shown how PSA is a widely used biomarker to
predict biochemical recurrence in patients treated for prostate cancer.
Similarly, serum bilirubin is used to monitor primary biliary cirrhosis
progression.
2. The interest may be on the longitudinal outcome but this is compli-
cated by potentially informative dropout, which may be viewed as a
time-to-event outcome. For example, in a study where the goal is to
compare diﬀerent treatments, participants may dropout from the study
since they feel much better or, on the contrary, they do not see any im-
provement from the therapy. Thus, dropout is nonrandom, but linked
to treatment eﬀect;
3. The interest may be on the relationship between the longitudinal and
the time-to-event outcome so that both types of outcome are of pri-
marily interest. This setting often arise when the association between
the biomarker trajectory and the time-to-event outcome needs to be
assessed. For example, the goal may be to verify if hemoglobin level
can predict renal graft failure.
The ﬁrst setting is the one that will be considered in this thesis from now
on. More speciﬁcally, our interest will be in predicting survival probabilities
using models which exploit all the information available from longitudinal
measurements of a speciﬁc biomarker. In Section 2.2, the traditional ap-
proach for the analysis of survival data will be presented along with the
problems arising from the necessity to incorporate the information from a
time-dependent covariate,i.e. the longitudinal response, measured intermit-
tently and possibly with error. In Section 2.3, the three methods developed
to solve these problems are presented.
162.2 The traditional approach for analyse time-
to-event data
The traditionally used survival model for the analysis of time-to-event data
is the relative risk (Cox) model (Cox 1972). As other survival regression
models, it is used to ﬁnd any possible relationship between survival times
and important covariates. The main reason why standard regression models
(e.g. linear regression model, logistic regression model, etc.) will often be
inappropriate is that survival times may be censored. Censoring occurs when
incomplete information is available about the survival time of some individ-
uals. There are three types of cesoring: left censoring, interval censoring,
and right censoring. When the event of interest already occurred before the
beginning of the study, the event time is said to be left censored. When the
event occurred in a time interval but we do not know the exact time point,
the event time is interval censored. Finally, when the event did not occur
while the subject was under study, the event time is right censored. This
last type of censoring happens, for example, because the medical study ends
before each patient experiences the event, or because the patient drops out
of the study prematurely. In both cases, we only know that the patient will
possibly experience the event in the future but we do not know exactly when.
Since right censoring is the most common type of censoring in clinical trials
and observational studies, we assume survival data to be subjected to right
censoring.
Let Ti be the time to an event of interest, called survival time, for the
i-th subject (i = 1,2,...,n). Ti is taken as the minimum of the true event
time T ∗
i and the censoring time Ci. Therefore, we observe Ti = min(T ∗
i ,Ci).
Furthermore, we deﬁne the event indicator as δi = I(T ∗
i ≤ Ci), where I( )
is the indicator function that takes the value 1 if the event is observed (i.e.
T ∗
i ≤ Ci), and 0 otherwise. Moreover, let zi be the vector of baseline (time =
0) covariates (e.g. gender, height, ethnicity, treatment indicator, etc.), mea-
sured before or at the beginning of the study. For the longitudinal outcome,
17we consider only the case of a single covariate which is measured repeatedly
over time. Let yi(t) denote the value of the longitudinal outcome at the time
point t for the i-th subject. It is important to emphasize that we do not
actually observe yi(t) at all time points, but only intermittently, at speciﬁc
time points tij at which the measurements were taken. Moreover, although
visit times usually follow a time schedule, some participants could not follow
it perfectly so that the times at which the longitudinal covariate is collected
and the ﬁnal number of covariate values can be diﬀerent for each individ-
ual. Therefore, the observed longitudinal data consist of the measurements
yi = {yi(tij),j = 1,2,...,ni}, where ni is the number of measurements avail-
able for subject i. Overall, the observed data available for each individual is
(Ti,δi,zi,yi). We assume that censoring is non-informative in that, given zi
and yi, the event and censoring time for the i-th patient are independent.
In survival regression models, the common approach is to model the haz-
ard function rather than the means functions as in classical regression models.
The hazard function, also called risk function, is deﬁned as (Wu 2010)
h(t) = lim
∆t→0
P(t ≤ T ∗ < t + ∆t | T ∗ ≥ t)
∆t
, t > 0,
which is the risk or hazard of death (or event) at time t, i.e., the probability
that an individual experiences the event at time t given that he/she has
survived to time t. Another essential function in survival analysis is the
survival function, which is deﬁned as
S(t) = P(T
∗ ≥ t) = 1 − F(t), t > 0,
where F(t) = P(T ∗ < t) is the usual cumulative distribution function (cdf).
Survival at time t, i.e. S(t), is the probability that an individual survives at
least to time t. This two functions are strongly linked as it can be seen from
the following formula:
18h(t) = −
d
dt
log(S(t)), t > 0,
The probability density function can be deﬁned as
f(t) = h(t)S(t), t > 0,
Therefore, the probability distribution of the observed data (Ti,δi) is given
by
f(Ti,δi) ∝ f(Ti)
δiS(Ti)
1−δi = hi(Ti)
δiSi(Ti), Ti > 0,
In order to quantify the eﬀect of yi(t) and zi on the risk for an event, we may
use a relative risk model of the form (Thernau and Grambsch 2000)
hi(t | Yi(t),zi) = lim
dt→0
Pr(t ≤ T
∗
i < t + dt | T
∗
i ≥ t,Yi(t),zi)/dt
= h0(t)exp
 
γ
Tzi + αyi(t)
 
, (2.1)
where Yi(t) = {yi(u),0 ≤ u < t} denotes the history of the longitudinal pro-
cess up to time point t, h0(t) denotes the baseline hazard function (i.e. the
hazard function of a hypothetical individual with all covariates equal to zero),
γ is a vector of regression coeﬃcients related to the vector zi, and α is the
regression coeﬃcient which quantiﬁes the eﬀect of the longitudinal outcome
on the risk for an event. In the classical relative risk Cox model (Cox 1972),
the baseline hazard function h0(t) is left unspeciﬁed. This is due to the fact
that a hazard function may be too complicated to be modeled parametri-
cally so that we can avoid a parametric assumption about its distribution
and model it ﬂexibly though nonparametric estimators. For this reason, the
19relative risk Cox model is a semiparametric model: while a parametric form
is assumed for the covariate eﬀect, the baseline hazard function is treated
nonparametrically.
In order to estimate parameters γ and α, statistical inference can be based
on the likelihood method. In particular, Cox (1975) suggested to maximize
not the entire likelihood function, but the part of it that contains all and
only the regression parameters. This part is called partial likelihood and is
deﬁned as
L(γ,α) =
n  
i=1
 
exp(γTzi + αyi(Ti))
 n
j=1 exp(γTzi + αyi(Ti))I(Tj > Ti
 δi
(2.2)
This is treated as a usual likelihood, and inference is carried out as usual.
Nevertheless, it should be remember that it is not a likelihood in the ordinary
sense of the word. It can be used for parameter estimation but any probability
interpretation should be avoided (Kalbﬂeisch and Prentice 2002). Looking
at (2.2) it can be noted that, thanks to the event indicator δi, the numerator
depends only on the information from the individual who experienced the
event, while the denominator uses all the information from individuals who
had not experienced the event yet. This formula is only valid when there are
no ties between the event times, that is, there are no events which happened
at the same time. Indeed, it is usually assumed that the events actually
happen in a continuous time so that two event times cannot happen at the
same time. In real datasets, however, due to grouping and rounding, the
recorded event times may coincide. Thus, several suggestions for handling
ties in the partial likelihood can be found in the literature. The two most
used belong to Breslow (1974) and Efron (1977) (see Klein and Moeschberger
2003 for more details).
It should be noted that, in order to be able to implement (2.2), several
problems need to be solved. Fist, we need to know the value of y(t) for
each individual still alive at each observed event time. In practice, as al-
ready said, y(t) is only available intermittently for each subjects. In fact, if
20we think about post-treatment PSA value, it could be measured at approx-
imately 6-months intervals or even once a year. This leads to missing data
in time-dependent covariates in the survival model. Second, longitudinal
covariates may be measured with error, such as PSA level, blood pressure,
CD4 count, or viral load. The consequence is that the observed covariate
values, i.e. yi, are not their true values but mis-measured one. If covariate
measurement errors are ignored in regression models, parameter estimates
may be biased, hypothesis testing may lose power, and important features
in the data may be masked. In our case, if covariate measurement errors are
not taken into account, true covariate eﬀects may not be correctly estimated
or even detected. In fact, assessing the eﬀect of measurement error in a lon-
gitudinal covariate on the parameter estimates of the Cox model, Prentice
(1982) showed that the presence of measurement error causes the estimated
parameters to be biased towards the null. Therefore, covariates with a strong
prognostic eﬀect could be considered of low importance and be discarded.
Let mi(t) denote the true and unobserved value of the longitudinal out-
come at time t. Then, if we need to account for measurement error, the
correct hazard function and partial likelihood on which statistical inference
should be based are
hi(t | Mi(t),zi) = lim
dt→0
Pr(t ≤ T
∗
i < t + dt | T
∗
i ≥ t,Mi(t),zi)/dt
= h0(t)exp(γ
Tzi + αmi(t)), (2.3)
where Mi(t) = {mi(u),0 ≤ u < t} denotes the true unobserved longitudinal
process up to time point t; and
L(γ,α) =
n  
i=1
 
exp(γTzi + αmi(Ti))
 n
j=1 exp(γTzj + αmj(Ti))I(Tj > Ti)
 δi
In Section 2.3, the most widespread methods proposed to address missing
21data in the longitudinal outcome and to take into account measurement error
are presented.
2.3 Methods for missing values and measure-
ment error
2.3.1 Last Value or Last Observation Carried Forward
(LVCF or LOCF)
This method is well described by Molenberghs and Kenward (2007) and it
consists in replacing the missing value with the last available value. In our
case, the missing value of the longitudinal outcome would be substituted by
the value measured during the nearest preceding visit time. However, the
simplicity of this approach cannot overcome its disadvantages. In fact, to
ensure the validity of this method, very strong and often unrealistic assump-
tions have to be made. Fist, it has to be assumed that the subject’s value of
the covariate between two measurements times is constant. Clearly, this as-
sumption is not biologically plausible since it is diﬃcult to think that highly
variable measures, such as CD4 counts for HIV patients, stay unchanged be-
tween two visit times (Bycott and Taylor 1998). Second, it treats observed
values and imputed ones on the same level. Third, it does not consider the
measurement error issue at all.
2.3.2 Two-stage approach
The subsequent approach proposed to reduce bias in parameter estimates
was the two-stage approach. In the ﬁrst stage, a model for the longitudinal
process is ﬁtted ignoring the survival outcome. Usually, a linear mixed eﬀect
model (LME) is used. Then, in the second stage, a survival model, often
the relative risk model, is ﬁtted using the subject-speciﬁc predictions of the
time-dependent covariate based on the longitudinal model. This approach
22showed to reduce bias compared to the simpler LVCF without completely
eliminating it. Wu (2010, Chapter 8) reports two sources of bias character-
izing this approach. First, the longitudinal outcome does not consider the
possibility that the covariate trajectories of subjects who experienced the
event or dropped out from the study may be diﬀerent from those who were
still alive at the end of the study. In this case the bias is due to the informa-
tive dropout, and may depend “on the strength of the association between
the longitudinal process and the survival process”. Second, since the infer-
ence in the second stage completely ignores the estimation uncertainty in the
ﬁrst stage, the standard errors may be under-estimated.
2.3.3 Joint models
The persistent bias characterizing parameter estimates of the two previous
methods conducted researchers to focus their study on an approach based
on the joint likelihood of all observed longitudinal and survival data. Since
all parameters in the longitudinal and survival models are simultaneously
estimated, the joint likelihood method avoids much of the bias in the previous
two methods and provides the most eﬃcient estimation if the assumed models
are correct. Wulfsohn and Tsiatis (1997) were the ﬁrst authors who proposed
this approach assuming a relative risk model for the survival times with an
unspeciﬁed baseline risk function. After them, many other researchers tried
to extend their work by testing diﬀerent model formulations (Proust-Lima
and Taylor 2009; Yu, Taylor, and Sandler 2008; Henderson, Diggle, and
Dobson 2000), assumptions validity (Rizopoulos and Verbeke 2008; Hsieh,
Tseng and Wang 2006; Brown, Ibrahim, and DeGruttola 2005; Tsiatis and
Davidian 2004), and suggesting improved estimation techniques (Rizopoulos,
Verbeke, and Lesaﬀre 2009; Tsiatis and Davidian 2001).
In Chapter 3, the joint modeling approach will be formally presented and
discussed in detail.
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Joint modeling of longitudinal
and survival data
3.1 Introduction
Joint models were developed in order to properly answer the three principal
interests already presented in 2.1. In summary, when emphinternal1 time-
dependent covariates are involved in survival analises, we need to account
for their special characteristics in order to obtain valid inferences. Similarly,
when the interest is on the longitudinal outcome, ignoring a possible non-
random dropout process, may lead to biased estimates. In both cases, the
class of joint models for longitudinal and time-to-event data constitutes a
promising modeling paradigm to resolve these issues.
Tsiatis and Davidian (2004) state that a joint model is comprised by
two linked sub-models, one for the ‘true’ longitudinal process mi(t) and one
for the event time T ∗
i , along with additional speciﬁcations and assumptions,
which allow ultimately a full representation of the joint distribution of the
1An internal covariate is “typically the output of a stochastic process which is generated
by the individual under study and in many instances is observed as long as the individual
survives and is uncensored” (Kalbﬂeisch and Prentice 2002). Thus, biomarkers such as
blood pressure, PSA level, CD4 count are examples of internal variables. The diﬀerence
between internal and external covariates will be further discussed in Section 4.2.
25observed data {Ti,δi,yi,ti,zi}, where ti = (ti1,...,tini)T.
At the end of Chapter 2, it was mentioned that a variety of models has
been considered in the joint modeling literature. Therefore a choice needs to
be made. For the remainder of this work, we will adopt those models ﬁrstly
suggested by Wulfsohn and Tsiatis (1997) for joint models: a Gaussian linear
mixed eﬀect model for the longitudinal response and a relative risk model
for the event times. The survival sub-model has already been described in
Section 2.2 and is deﬁned by the hazard function (2.3), but a modiﬁcation
has to be introduced. So far the baseline hazard function h0(t) has been
left unspeciﬁed and thus estimated nonparametrically. However, for reasons
which will be explained in Section 3.3.2, within the joint modeling framework,
a parametric function should be employed. We could opt for a standard
survival distribution such as the Weibull or Gamma distributions, or for
more ﬂexible solutions such as step functions or splines. In the following,
ω will be the vector containing the parameters describing the parametric
hazard function h0(t).
In Section 3.2, the problem of how to properly model the longitudinal pro-
cess is addressed, while in Section 3.3, likelihood formulation and estimation
will be described.
3.2 The measurement error model
In order to obtain non biased parameter estimates for γ and α in (2.3), it is
crucial to estimate mi(t) and successfully reconstruct the complete longitudi-
nal history, using the available measurements. It is considered appropriate to
use the model known as classical measurement error model (Wu 2010, Chap-
ter 5). Let yi(tij) be the observed covariate value for the i-th individual at
time tij, i = 1,...,n, j = 1,...,ni, and let mi(tij) be the corresponding unob-
served true covariate value. The classical measurement error model assumes
that
26yi(tij) = mi(tij) + ei(tij), E(ei(tij)|mi(tij)) = 0, i = 1,...,n; j = 1,...,ni
where ei(tij) represents the measurement error (and the possible biological
variation) at time tij.
To model the true time-dependent covariate mi(t), it is common to assume
that the covariate values change smoothly over time and thus a linear mixed
eﬀect model (LME) is the standard choice (Tsiatis and Davidian 2004). A
LME model allows to take into account between-individual variation and
within-individual correlation. In fact, Diggle et al. (2007) state that “when
the goal is to understand the joint evolution of measurement and time-to-
event at the level of an individual subject, we would favor random eﬀects
models”, to whom LME belongs. More speciﬁcally, the chosen LME has the
form
yi(t) = mi(t) + ei(t) = ui(t)
Tβ + vi(t)
Tbi + ei(t), i = 1,...,n,
where ui(t) and vi(t) are known row vectors of the design matrices for the
ﬁxed and random eﬀects, respectively, β is the vector containing unknown
ﬁxed parameters, bi is the vector containing the random eﬀects, and ei(t) is
the measurement error term. We assume that bi and ei(t) are independent,
and ei(t) ∼ N(0,σ2) so that the within-individual covariate measurements
are assumed to be conditionally independent given the random eﬀects. This
assumption is reasonable if the measurement times are suﬃciently far apart
that within-subject autocorrelation among observed values is essentially ig-
norable, or if the measurement error is large in comparison with biological
ﬂuctuations (Tsiatis and Davidian 2004). Therefore, at any given time tij,
the unobserved true covariate value can be taken as
mi(tij) = ui(tij)
Tβ + vi(tij)
Tbi, i = 1,...,n; j = 1,...,ni.
27One of the most discussed distributional assumptions is that of the ran-
dom eﬀects bi with the multivariate normal distribution with mean zero and
covariance matrix D, i.e. bi ∼ N(0,D) being the usual choice. Verbeke et al.
(2010, Chapter 2) underline two reasons causing the concern that relying on
standard distributions, within the joint modeling framework, may inﬂuence
the derived inferences. “First, the random eﬀects have a more prominent role
in joint models, because on the one hand they capture the correlations be-
tween repeated measurements in the longitudinal outcome and on the other,
they associate the longitudinal outcome with the event process. Second, joint
models belong to the general class of shared parameter models, and corre-
spond to a non-random dropout mechanism. [...] As it is known from the
missing data literature, handling dropout can be highly sensitive to modeling
assumptions”. Studies comparing estimates from models with normal ran-
dom eﬀects and with a more ﬂexible distribution suggest a sort of robustness
of the joint likelihood approach with normal random eﬀects to departures
from this assumption (Song et al. 2002, Davidian and Tsiatis 2004). Such
robustness is seen both in parameter estimates and standard errors. This
empirical conclusion has been recently corroborated from a theoretical point
of view by Rizopoulos et al. (2008). They showed that, as the number of
repeated measurements per subject ni increases, misspeciﬁcation of the ran-
dom eﬀects’ distribution has a minimal inﬂuence in parameter estimators and
standard errors. In order to obtain good estimates of mi(t), it is important
to adequately specify ui(t) and vi(t) so that interesting features of the each
subject’s longitudinal trajectory can be captured. More speciﬁcally, when
the interest is in modeling the longitudinal component only and not to make
inference from it, and the covariate shows highly non-linear longitudinal tra-
jectories, a linear mixed model where ui(t) and vi(t) are expressed in terms
of high-order polynomials or splines2 is strongly recommended. Particularly,
2In mathematics a spline is a suﬃciently smooth piecewise-polynomial function. In the
context of longitudinal data analysis, they are used to ﬁt curves with a ﬂexible but smooth
form that is determined by the data. A detailed description about the use of splines in
linear mixed eﬀect models is given by Fitzmaurice et al. (2008, Chapter 11).
28the use of splines allows researchers not to make rigid assumptions about
the path of the biomarker over time and thanks to the subject speciﬁc ran-
dom eﬀects can well describe individuals’ proﬁles across time. Indeed, Brown
et. al (2005) aﬃrm that, since “the model is able to change rapidly to re-
ﬂect changes in the biomarkers over time, it may be preferable to parametric
models for many types of data”. The most used type of spline is the cubic
B-spline. In comparison with other B-splines with a higher degree, the cubic
B-splines ensures a great ﬂexibility with a restricted number of parameters.
3.3 Likelihood formulation and estimation
The main estimation methods that have been proposed for joint models are
based on a likelihood approach (Hsieh et al. 2006, Henderson et al. 2000,
Wulfsohn and Tsiatis 1997) and a Bayesian approach developed via Markov
chain Monte Carlo techniques (Hanson et al. 2011, Chi and Ibrahim 2006,
Brown and Ibrahim 2003). In this work, we use the classical maximum
likelihood method to obtain parameter estimates for the joint model.
3.3.1 Likelihood formulation
In the following part, according to the context, f( ) will be used as generic
notation for distributions, densities, or likelihood contributions.
First of all, we need to deﬁne the joint distribution of the time-to-event
and longitudinal outcomes {Ti,δi,yi}. Before doing that, however, there are
two assumptions which need to be made:
1. It is assumed that “the vector of time-independent random eﬀects bi
underlies both the longitudinal and survival processes. This means that
these random eﬀects account for both the association between the lon-
gitudinal and event outcomes, and the correlation between the repeated
measurements in the longitudinal process”, i.e. corr{ei(ts),ei(tk)} = 0,
for ts  = tk (Rizopoulos 2010). This assumption is also known as the
29conditional independence assumption and, omitting covariates in the
notation, can be formalised as
f(Ti,δi,yi|bi;θ) = f(Ti,δi|bi;θ)f(yi|bi;θ) (3.1)
f(yi|bi;θ) =
ni  
j=1
f {yi(tij)|bi;θ}, (3.2)
where θT = (θT
t ,θT
y ,θT
b ) denotes the parameter vector, with θt denot-
ing the parameters for the survival outcome, θy the parameters for the
longitudinal outcomes and θb the parameters of the random eﬀect co-
variance matrix D, yi is the row vector containing the ni longitudinal
responses of the i-th subject. As it can be seen from (3.1) and (3.2), the
conditional independence assumption allows the deﬁnition of separate
models for the longitudinal and the survival outcomes by conditioning
on the shared random eﬀects bi.
2. “Both the censoring mechanism and the visiting process (i.e., the stochas-
tic mechanism that generates the time points at which the longitudinal
measurements are collected) are non-informative, and thus they can be
ignored” (Verbeke et al. 2010). If we deﬁne the observed longitudi-
nal history as all the information available for the longitudinal process
prior to time point t, i.e., Yi(t) = {yi(u),0 ≤ u < t}, this assumption
implies that the decision on whether a subject drops out from the study
or appears at the study center for the scheduled visit depends only on
Yi(t) (and possibly on baseline covariates) and there is no further de-
pendence on future measurements or on other subjects characteristics
associated with the survival outcome but not taken into account.
We can now formulate the joint likelihood contribution for the i-th subject
as
f(Ti,δi,yi;θ) =
 
f(Ti,δi|bi;θt,β)
 
ni  
j=1
f {yi(tij)|bi;θy}
 
f(bi;θb)dbi, (3.3)
30where the likelihood of the survival part has the following form
f(Ti,δi|bi;θt,β) = {hi(Ti|Mi(Ti);θt,β)}
δi Si(Ti|Mi(Ti);θt,β), (3.4)
with hi( ) given by (2.3), and
Si(Ti|Mi(Ti),zi;θt,β) = Pr(T
∗
i > t|Mi(t),zi;θt,β)
= exp
 
−
  t
0
hi(s|Mi(s);θt,β)ds
 
, (3.5)
f {yi(tij)|bi;θy} is the univariate normal density for the longitudinal re-
sponses, and f(bi;θb) is the multivariate normal density for the random ef-
fects.
An important feature about the relative risk model considered here is
underlined by (3.5): the risk for an event at time t is assumed to depend
on the longitudinal history Mi(t) only through the current value of the
time-dependent covariate mi(t), whereas the survival function depends on
the whole history. This is another reason why, in order to obtain accurate
predicted survival probabilities, it is important to properly model the longi-
tudinal outcome.
3.3.2 Maximum likelihood estimation
Maximization of the likelihood function (3.3) with respect to θ is a compu-
tationally challenging task and it is the major drawback that prevented a
higher diﬀusion of joint models. In particular, both the integrals with re-
spect to the random eﬀects in (3.3), and the integral in the deﬁnition of the
survival function (3.5) do not usually have an analytical solution.
Tsiatis and Davidian (1997) were the ﬁrst who proposed to use the
expectation-maximization (EM) algorithm to maximize the joint likelihood
of the observed data and thus obtain parameter estimates. The EM algo-
rithm is an iterative method used to ﬁnd maximum likelihood estimates of
parameters when in the likelihood unobserved variables are present. The EM
algorithm alternates between an E-step, which computes the expectation of
31the log-likelihood using the current parameter estimates, and an M-step,
where new parameter estimates are computed by maximizing the expected
log-likelihood found with the E-step. These new parameter estimates are
then used to determine the distribution of the latent variables in the next
E-step. Fitzmaurice et al. (2008, Chapter 15) give a simple presentation of
the EM algorithm applied in the joint modeling framework where the random
eﬀects are treated as unobserved variables (all parameters are combined into
in the vector θ:
• Step 1: obtain initial parameter estimates through separate analyses of
the longitudinal and survival data. Thus, the required random eﬀects
are included in the longitudinal model but not in the survival model.
The parameter association between the longitudinal covariate and the
event time, i.e. α, is set to zero.
• Step 2: write down the combined conditional log-likelihood l(θ;yi,Ti,δi,bi)
of the observed data given random eﬀects bi.
• Step 3: obtain the conditional expectation of each function of bi, i.e.
g(bi), appearing in l(θ;yi,Ti,δi,bi), given (yi,Ti,δi) and using the cur-
rent estimates of θ.
• Step 4: replace each function of bi appearing in l(θ;yi,Ti,δi,bi) by
its conditional expectation. Maximize the obtained log-likelihood to
update the estimate of θ.
• Step 5: Iterate step 3 and 4 until convergence.
Steps 3 and 4 are the E-step and the M-step, respectively. In the E-step,
the conditional expectations of several functions of the non observed random
eﬀects, i.e. g( ), often involve intractable integrals of the form
E
 
g(bi)|yi,Ti,δi; ˆ θ
 
=
 
g(bi)f(bi|yi,Ti,δi; ˆ θ)dbi
32where ˆ θ is the value from the M-step of the previous iteration. In order to
make the computation of feasible, Wulfsohn and Tsiatis (1997) noticed that
f(Ti,δi|yi,bi) = f(Ti,δi|bi) and used two integrals instead of one:
E
 
g(bi)|yi,Ti,δi; ˆ θ
 
=
 
g(bi)f(bi|yi,Ti,δi; ˆ θ)dbi
=
 
g(bi)f(yi,δi|bi; ˆ θ)f(bi|yi; ˆ θ)dbi  
f(yi,δi|bi; ˆ θ)f(bi|yi; ˆ θ)dbi
(3.6)
At this point we can take advantage of the last form (3.6) and use numerical
integration to solve both integrals. Standard numerical integration tech-
niques such as Gaussian quadrature and Monte Carlo methods are usually
applied (Wulfsohn and Tsiatis 1997, Henderson et al. 2000, Wu 2010). The
use of Laplace approximations has recently been discussed by Rizopoulos et
al. (2009) in situations where a large number of random eﬀects is involved
(e.g., when splines are used in the random eﬀects design matrix).
The M-step is more straightforward since closed-form maximum likeli-
hood estimates for parameters D and σ2 are available. On the contrary,
maximum likelihood estimates for parameters β, γ, and α do not have a
closed-form solution and therefore are computed using the Newton-Raphson
method (see Rizopoulos et al. (2009) for more details).
We wish to go back for a moment to the choice made at the end of Sec-
tion 3.1 about the risk function h0(t). Although this function is typically left
unspeciﬁed, in the joint modeling framework Hsieh et al. (2006) warned re-
searchers from using the Fisher Information to obtain parameters’ standard
errors since their values would be underestimated. According to the au-
thors, this problem arises from the fact that “the nonparametric maximum
likelihood for h0(t) cannot be solved explicitly under the random eﬀect struc-
ture”. Furthermore, this causes the maximum proﬁle likelihood estimates of
the other parameters to be implicit as well since they depend on h0(t). Con-
sequently, the authors suggested to use the bootstrap technique to compute
the standard errors but its validity has not been proven yet. We choose then
to estimate parametrically the risk function h0(t) so that the usual para-
33metric asymptotic arguments for the maximum likelihood estimates can be
applied.
34Chapter 4
Individual survival probability
estimation
4.1 Introduction
In Chapter 1 we have shown how the need of accurate prognoses has increased
in the last decades in everyday medical practice. In particular, the possibility
of obtaining survival probabilities based on characteristics of the speciﬁc
patient would greatly help physicians in their decision making and patient
counseling, thus improving clinical output.
In the joint modeling framework, the interest on subject-speciﬁc predic-
tions for either the longitudinal or survival outcomes has increased in recent
years (Sweeting and Thompson 2011; Proust-Lima and Taylor 2009; Yu, Tay-
lor and Sandler 2008; Taylor, Yu, and Sandler 2005). In these studies, the
prognostic information contained in longitudinal measurements of covariates,
such as biomarkers, has been used to make predictions about patients’ sur-
vival probabilities. However, this aspect needs to be further analysed and
tested in order to be safely used in clinical practice.
Using the joint modeling formulation presented in Chapter 3, Rizopoulos
(2011) proposed a Monte Carlo approach to estimate survival probabilities
and their standard errors based on the output of a ﬁtted joint model. In par-
35ticular, the author considered dynamic subject-speciﬁc predictions, and il-
lustrated how survival probabilities are updated as additional measurements
of the longitudinal outcome are available. In Section 4.2 we will formally
present this approach and then, in Chapter 5, we will use it to predict pa-
tients’ survival.
4.2 Expected survival probabilities
The interest lies in predicting survival probabilities for a new subject i which
has provided a set of longitudinal measurements Yi(t) = {yi(s);0 ≤ s ≤ t}
(dependence on baseline covariates is assumed but suppressed for ease of
exposition).
Before going any further, it is important to carefully take into account
the already mentioned feature typical of covariates such as, for example, PSA
level, blood pressure and serum bilirubin level. In our framework, yi(t) repre-
sents an internal time-dependent covariate. More speciﬁcally, Kalbﬂeisch and
Prentice (2002) identify two kinds of time-dependent covariates: external and
internal. The condition which is needed to be satisfy by a time-dependent
covariate x(t) in order to be external is
Pr(x(t) | x(u),T ≥ u) = Pr(x(t) | x(u),T = u), 0 < u ≤ t. (4.1)
The direct consequence is that, whereas the covariate x( ) may inﬂuence
the event mechanism over time, its future path up to any time t > u is not
aﬀected by the occurrence of an event at time u. A type of external covariate
is the baseline covariate for which x(t) = x. Its value is measured at the
beginning of the study and it will not change over time. Other examples of
external time-dependent covariates are treatment, air pollution, atmospheric
temperature. Those time-dependent covariates which do not satisfy condition
(4.1) are called internal. This type of covariates have the property that,
in order to be measured, the individual has to be alive and uncensored.
36Their path, thus, carries information on the time of dropout. Since the
covariate yi(t) considered here is internal, a subject who provides longitudinal
measurements up to time t gives also the information that he/she was alive
and uncensored at that time.
Hence, it is more appropriate to focus on the conditional probability of
surviving time u > t given survival up to time t, that is,
πi(u | t) = Pr(T
∗
i ≥ u | T
∗
i > t,Yi(t),n ;θ), (4.2)
where n = {Ti,δi,yi;i = 1,...,n} denotes the sample on which the joint
model was ﬁtted and on which we wish to base our predictions. Using the
assumption that the vector of random eﬀects bi undelies both the longitudinal
and survival process (assumption formalized by (3.1)), Rizopoulos (2011)
observed that (4.2) can be written as
Pr(T
∗
i ≥ u | T
∗
i > t,Yi(t);θ)
=
 
Pr(T
∗
i ≥ u | T
∗
i > t,Yi(t),bi;θ)f(bi | T
∗
i > t,Yi(t);θ) dbi
=
 
Pr(T
∗
i ≥ u | T
∗
i > t,bi;θ)f(bi | T
∗
i > t,Yi(t);θ) dbi
=
 
Si {u | Mi(u,bi,θ);θ}
Si {t | Mi(t,bi,θ);θ}
f(bi | T
∗
i > t,Yi(t);θ) dbi, (4.3)
where Si( ) is given by (3.5). It is important to notice that the longitudinal
history Mi( ), approximated by the measurement error model presented in
Section 3.2, is a function of both the random eﬀects and the parameters.
At this point, a ﬁrst order estimate of πi(u | t) can be obtained using
the empirical Bayes estimate of bi. However, the derivation of its standard
error and or conﬁdence interval is rather diﬃcult since we need to take into
account the variability of both the maximum likelihood and empirical Bayes
estimates. To overcome this problem and produce a valid standard error for
the estimate of πi(u | t), Rizopoulos (2011) proposes to follow an asymptotic
37Bayesian formulation of the joint model and therefore derive the posterior
expectation of (4.2), which can be written as
πi(u | t) = Pr(T
∗
i ≥ u | T
∗
i > t,Yi(t),n )
=
 
Pr(T
∗
i ≥ u | T
∗
i > t,Yi(t);θ)p(θ | n) dθ. (4.4)
The ﬁrst part of the integrand is given by (4.3). The second part is the
posterior distribution of the parameters given the observed data. The author,
using arguments of the standard asymptotic Bayesian theory, assumes that
the sample size n is large enough such that {θ | n} can be well approximated
by N(  θ,   Var), with   Var =   var(  θ). Then, in order to obtain a Monte Carlo
estimate of πi(u | t), he proposes the following simulation scheme:
• Step 1: Draw θ(l) ∼ N(  θ,   Var).
• Step 2: Draw b
(l)
i ∼
 
bi | T ∗
i > t,Yi(t),θ(l) 
.
• Step 3: Compute
π
(l)
i (u | t) =
Si
 
u | Mi(u,b
(l)
i ,θ(l));θ(l)
 
Si
 
t | Mi(t,b
(l)
i ,θ(l));θ(l)
  . (4.5)
• Step 4: Repeat Steps 1-3 for each subject i, l = 1,...,L times, where
L denotes the number of Monte Carlo samples.
If Steps 1 and 3 are straightforward to perform, the posterior distribution
of the random eﬀects given the observed data in Step 2 is not of standard
form. Thus, the author proposes to use the Metropolis-Hastings algorithm1
1The Metropolis-Hastings algorithm is a Markov chain Monte Carlo method used to
simulate complex, nonstandard multivariate distributions. The M-H algorithm is based on
proposing values sampled from an instrumental distribution, which are then accepted with
a certain probability that reﬂects how likely it is that they are from the target distribution
(Chib and Greenberg 1995). In our case, the instrumental distribution coincides with the
multivariate t distribution while the target distribution is the multivariate distribution of
bi.
38with independent proposals from a multivariate t distribution centered at the
empirical Bayes estimated   bi, with scale matrix
  var(  bi) =
 
−
∂2
∂bT∂b
logf(T
∗
i > t,Yi(t),b;   θ)
 
 
 
b=b bi
 −1
,
and four degrees of freedom. The author chooses a multivariate t pro-
posal for two reasons. First, with other two collegues, he has recently
shown that, as ni increases, the leading term of the log posterior distri-
bution of the random eﬀects is the logarithm of the density of the LMM
model logf
 
Yi(t) | bi;θ(l) 
=
 
j logf
 
yi(tij) | bi;θ(l) 
, which is quadratic
in bi and will resemble the shape of a multivariate normal distribution (Ri-
zopoulos, Verbeke and Molenberghs 2008). Second, if ni is small, the heavier
tails of the t distribution will ensure suﬃcient coverage.
Once the realizations π
(l)
i (u | t), l = 1,...,L are available, we can derive
estimates of πi(u | t), such as
  πi(u | t) = median
 
π
(l)
i (u | t), l = 1,...,L
 
(4.6)
or
  πi(u | t) =
1
L
L  
i=1
π
(l)
i (u | t). (4.7)
The standard error of ˆ πi(u | t) can be computed using the sample variance
over the Monte Carlo samples, while its conﬁdence interval can be obtained
using the Monte Carlo sample percentiles.
Both (4.2) and (4.5) formally show how the expected survival probability
is forced to be equal to 1 while u ≤ t and then, when u > t, is allowed to
decrease. Moreover, the estimates of πi(u | t) can easily be updated when
new covariate measures are available. In fact, in Step 2, the multivariate t
distribution of the random eﬀects bi is based on the whole individual covariate
history Yi(t).
394.3 Considering alternative association struc-
tures
So far we have used the standard association structure for the joint model
formulation, that is, the risk for an event at a speciﬁc time point t depends
on the true level of the longitudinal covariate at the same time point. Its
hazard function is deﬁned as
hi(t) = h0(t)exp
 
γ
Tzi + α1mi(t)
 
where the parameter α1 incorporates the strength of the association between
the current level of the covariate and the risk. However, as Fisher and Lin
(1999) noticed, “the choice of a time dependent covariate involves the choice
of a functional form for the time-dependence of the covariate. This choice
is usually not self-evident but may be suggested by biological understanding
or biological hypothesis”. The functional form issue needs to be properly
tackled since choosing the wrong covariate functional form may substantially
inﬂuence the derived results. The aim of this work is exactly that of verify
whether diﬀerent association structures (which can be practically considered
as functional forms) actually inﬂuence individual survival probabilities and
to individuate possible patterns characterizing these diﬀerences.
In the following we present seven alternative parameterizations to the
standard parameterization which can be use to model the association be-
tween the covariate and the risk.
Slope parameterization
As we have seen in Chapter 1, the CD4 cell counts is a good longitudinal
covariate which helps to monitor HIV progression. A decreasing CD4 count
over time indicates a worsening of patient health. On the contrary, in pa-
tients with PBC, an increasing serum bilirubin level indicates a worsening of
patient condition since it means that the liver is failing. In both cases, the
slope could be a good prognostic factor since it indicates the rate at which
40CD4 count and serum bilirubin level is respectively decreasing or increasing.
In general, the slope of the longitudinal trajectory can be a good indicator of
the velocity with which the disease is progressing. The relative risk survival
sub-model takes the form
hi(t) = h0(t)exp
 
γ
Tzi + α2m
′
i(t)
 
where
m
′
i(t) =
d
dt
mi(t) =
d
dt
 
u
T
i (t)β + v
T
i (t)bi
 
.
Parameter α2 measures how strongly associated is the value of the slope of
the true longitudinal trajectory at time t with the risk for an event at the
same time point.
Current value + Slope parameterization
This parameterization incorporates into the model both the information
about the value of the true covariate at time t and the value of the slope at
the same time point. With this parameterization we can distinguish between
patients with similar mi(t) values but with diﬀerent slopes. The relative risk
survival sub-model takes the form
hi(t) = h0(t)exp
 
γ
Tzi + α3mi(t) + α3.sm
′
i(t)
 
.
Parameter α3 measures the strength of the association between the true
value of the longitudinal covariate at time point t with the risk for an event
at the same time point, given that m
′
i(t) stays constant. Similarly, α3.s mea-
sures how strongly associated is the value of the slope of the true covariate
trajectory at time t with the risk for an event at the same time point, pro-
vided that mi(t) remains constant.
Cumulative eﬀect parameterization
The two previous parameterizations assume that the risk for an event at a
speciﬁc time point t depends on the true covariate level and/or slope value at
the same time point. However, this assumption may not be always realistic.
41Consider, for example, the eﬀect of smoking on the risk of heart attack. The
risk at time t of a patient who used to smoke 30 cigarettes per day and only
in the last period has started to smoke only 3 cigarettes per day may be
much higher than the risk of a patient who has always smoked 3 cigarettes
per day, being equal all the other covariates.
One method to account for the cumulative eﬀect of the longitudinal co-
variate to time point t is to use the integral of the true longitudinal trajectory
up to that time point. The relative risk survival sub-model takes the form
hi(t) = h0(t)exp
 
γ
Tzi + α4
  t
0
mi(s)ds
 
.
The parameter α4 measures the strength of the association between the risk
for an event at time point t and the area under the true longitudinal trajec-
tory up to the same time point, which is obtained through the integral value.
Weighted cumulative eﬀect parameterization
The cumulative eﬀect parameterization places the same weight for all past
values of the true longitudinal covariate. In situations where more recent
values have a stronger inﬂuence on the risk than previous values, this type of
parameterization may not be completely appropriate. In order to overcome
this problem, we could multiply mi(t) with a weight function that places
diﬀerent weights at diﬀerent time points and then compute the integrand of
the adjusted covariate. In this case, the relative risk survival sub-model takes
the form
hi(t) = h0(t)exp
 
γ
Tzi + α5
  t
0
g(t − s)mi(s)ds
 
,
where g( ) denotes the weight function. In this work, we have chosen to use
as weight function the standard normal density g(x) = exp(−x2/2). Since
the variance is equal to 1, in practice, the three most recent years of the true
covariate history Mi(t) are associated with the risk for death. The parameter
α5 measures the strength of the association between the risk for an event at
time point t and the area under the longitudinal trajectory of g(t−s)mi(s),
420 ≤ s ≤ t.
Lagged value parameterization
There are situations where the risk for an event at time point t is mainly
inﬂuenced by the covariate value at a previous time point. For example,
Cavender et al. (1992) analysed data from a study on patients with coronary
artery disease. Each patient was interviewed every 6 months and, among
other variables, his/her smoking status was recorder. Surprisingly, the au-
thors found that the estimated eﬀect of the current smoking was positive
although not statistically signiﬁcant. From the analysis of the individual pa-
tient smoking histories, it turned out that most of those who had died were
smokers, but many of them had stopped smoking at the last follow-up before
their death. The consequence was that many of the patients who died have
just quit smoking, whereas some of the patients who were still alive were
smoking. This explains why the model gave that unexpected result.
One way to address this problem is to use time-lagged covariates. In this
case, the relative risk survival sub-model takes the form
hi(t) = h0(t)exp
 
γ
Tzi + α6mi [max(t − c,0)]
 
.
With this parameterization we assume that the risk at time point t depends
on the true value of the longitudinal covariate at time t−c, where c speciﬁes
the time lag of interest. Parameter α6 measures how strongly associated is
the value of the true longitudinal covariate at time t−c with the risk for an
event at time point t.
Lagged slope parameterization
Similarly to what happen for the current slope parameterization, we can con-
sider the eﬀect of the slope value at time t − c on the risk at time t. The
relative risk survival sub-model takes the form
hi(t) = h0(t)exp
 
γ
Tzi + α7m
′
i [max(t − c,0)]
 
.
Parameter α7 measures how strongly associated is the value of the slope of
43the true longitudinal trajectory at time t − c with the risk for an event at
time point t.
Lagged value + lagged slope parameterization
The last parameterization which will be considered here involves both the
value of the true covariate and the slope of the true longitudinal trajectory
at time point t − c. The relative risk survival sub-model has the form
hi(t) = h0(t)exp
 
γ
Tzi + α8mi [max(t − c,0)] + α8.sm
′
i [max(t − c,0)]
 
.
Parameter α8 measures the strength of the association between the true
value of the longitudinal covariate at time point t − c with the risk for an
event at time point t, given that m
′
i(t−c) stays constant. Similarly, α8.s mea-
sures how strongly associated is the value of the slope of the true covariate
trajectory at time t − c with the risk for an event at time point t, provided
that mi(t − c) remains constant.
In Chapter 5 we will use a dataset based on a study involving patients diag-
nosed with primary biliary cirrhosis. We will compare the individual expected
survival probabilities given by the model using the standard parameterization
with those compute by the models using the other seven parameterizations.
However, the eight models will not contain any of the baseline covariates
zi. In fact, each model has its own estimates of the parameters contained
in the vector γ and this aﬀects models’ prediction. Since we want to study
the inﬂuence of the association structure on the expected survival proba-
bilities, the presence of the baseline covariates zi in the survival sub-model
would make it diﬃcult to distinguish between their eﬀect and that of the
association structure.
Furthermore, the reader could notice that also the values of the param-
eters deﬁning the parametric baseline hazard function h0(t) and the true
covariate trajectory are not usually the same. However, the inﬂuence of this
diﬀerences is small in most of the cases, although it should not be ignored a
priori, as we will see in Chapter 5.
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Comparing expected survival
probabilities: the PBC dataset
5.1 Primary biliary cirrhosis: the disease
The Mayo Clinic website reports that “primary biliary cirrhosis is a disease in
which the bile ducts in your liver are slowly destroyed. Bile, a ﬂuid produced
in your liver, plays a role in digesting food and helps rid your body of worn-
out red blood cells, cholesterol and toxins. When bile ducts are damaged,
as in primary biliary cirrhosis, harmful substances can build up in your liver
and sometimes lead to irreversible scarring of liver tissue (cirrhosis)”(Mayo
Clinic). At the moment, it is not clear what triggers this disease and it is
believed to have an autoimmune etiology.
The typical patient is a middle-aged women who reports fatigue and itch-
ing or who has no symptoms but has been found to have unexplained hep-
atomegaly or abnormal serum liver tests. The natural history of untreated
primary biliary cirrhosis (PBC) is one of gradual progression through four
phases: preclinical, asymptomatic, symptomatic (including systemic and por-
tal hypertensive), and liver insuﬃciency (Mayo 2008). Despite extensive
studies, medical therapy has not been shown to have a signiﬁcant impact
in slowing the progression of PBC so that the only truly eﬀective treatment
46is liver transplantation (Markus et al. 1989). Consequently, there has been
considerable interest in developing models which could accurately predict
patients’ survival probabilities in order to better individuate those who are
going to strongly need a new liver within a couple of years. In fact, it has
been found that, from diagnosis to liver failure, can pass more then 20 years
in asymptomatic patients (Pares and Rodes 2003).
Although the four phases are usually respected by most of the patients
(i.e. it is rare that a patient skips one phase), the velocity of disease pro-
gression can signiﬁcantly change from patient to patient: some patients will
have a relatively slow, benign clinical course whereas others will progress
more rapidly to portal hypertension and liver insuﬃciency. Thus, the ability
to identify surrogate markers of disease progression is extremely important.
Of the serum tests widely available, serum bilirubin is the single most use-
ful predictor of clinical outcome, although it does not become elevated until
later in the disease process (Mayo 2008).
Serum bilirubin level is the prognostic factor used in our analysis.
5.2 Description of the PBC dataset
This dataset contains information of 312 patients who were enrolled in two
clinical trials evaluating the use of D-penicillamine for treating PBC. Pa-
tients were followed from January 1974 through May 1984. The ﬁrst visit
was made at the study entry, the second after six months, the third after
one year and then at approximately 1 year intervals. However, as often hap-
pens in longitudinal studies, the visit schedule was not precisely followed. No
treatment beneﬁt in prolonging survival was found so that the follow up was
extended to April 30, 1988 in order to study the natural history of the PBC
disease, i.e. how the disease progresses in time and which factors may inﬂu-
ence such progression. By 1988, 140 (44.9%) patients died, 29 (9.3%) were
transplanted and the other 143 (45.8%) survived. As happened in previous
studies, transplanted patients were censored at the time of transplantation.
47At the end of the study, there were 1945 total visits. The median number of
serum bilirubin values per patient was 5, with a minimum of 1 and a max-
imum of 16 measurements. The median number of years in the study was
6.296, with a minimum of 0.1123 (i.e. 41 days) and a maximum of 14.31
years. Some baseline covariates, such as gender and age, were recorded at
the beginning of the study. Laboratory test results, such as serum biliribin,
albumin and alkaline phosphatase, were measured at each visit.
5.3 Description of the models
The analysis were done using the statistical software R. In particular, Ri-
zopoulos (2010a) presented the R package JM that can be used to ﬁt joint
models with the formulation proposed in this work. Before this package, only
a separate analysis of longitudinal and event time data was possible. The
procedure followed here to ﬁt the eight joint models is composed by three
steps:
• Step 1: ﬁt a proper mixed eﬀect model for the longitudinal covariate
(R package used: lme).
• Step 2: ﬁt a relative risk model for the survival part without using any
covariate (R package used: survival).
• Step 3: ﬁt the joint model using the parameterization that deﬁnes the
chosen association structure (R package used: JM).
• Step 4: repeat Step 3 for each of the remaining parameterizations.
In Step 1, we concentrate our attention on modeling the longitudinal tra-
jectory. Since serum bilirubin exhibits a right skewed shape distribution, its
logarithm is preferred (Fleming and Harrington 1991). For the remainder of
this work, our longitudinal covariate will be log(serBilir), where serBilir is
the label given to the original serum bilirubin covariate in the PBC dataset.
48A measurement error model with a quadratic trend was chosen to model
the longitudinal trajectory of log(serBilir). Therefore the model takes the
form
log(serBilir)i(t) = mi(t) + ei(t)
= (β0 + bi0) + (β1 + bi1)t + (β2 + bi2)t
2 + ei(t),(5.1)
where ei(t) ∼ N(0,σ2) and
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It should be kept in mind that, in this step, the parameter estimates are only
temporary. Their ﬁnal values will be calculated in Step 3, where also the
information from the survival part is taken into account. However, the non
signiﬁcance of the parameter β2 found in this temporary model persists in
all the ﬁnal longitudinal models (see Table 5.2). Nevertheless, we chose to
keep the ﬁxed quadratic term to preserve interpretability.
Step 2 is only a technical step used to create objects used by the JM package
in Step 3.
In Step 3, all the parameters are estimated simultaneously. Therefore, the
estimates of the survival part are also based on the information contained in
the longitudinal part, and vice versa. We used a piecewise constant function
to model baseline risk function h0(t). More speciﬁcally,
h0(t) =
Q  
q=1
ωqI(rq−1 < t ≤ rq),
where 0 = r0 < r1 < ... < rQ denotes the split of the time scale, with rQ
being larger that the largest observed time, and ωq denotes the value of the
49hazard in the interval (rq−1,rq]. In our case, Q = 7 and the six time points
that divide the time interval (0,rQ) are the quantiles of the observed event
times (Rizopoulos 2010b).
About the three models containing lagged covariate values and/or lagged
slopes, we used a lag equal to 2 years. In fact, in a separate analysis testing
for diﬀerent lag times where also baseline covariates were involved, the joint
model with a lag of 2 years was the best model, according to both the Akaike’s
Information Criterion (AIC) and Bayesian Information Criterion (BIC)1.
For ease of exposition, we have labeled with a short name the eight mod-
els corresponding to the eight diﬀerent parameterizations. See Table 5.1.
Furthermore, when not otherwise speciﬁed, we will use the noun ‘covariate’
to indicate the longitudinal variable log(serBilir) without the measurement
error, which coincides with mi(t) in (5.1).
Table 5.2 contains the estimates of the parameters belonging to the longi-
tudinal part of the joint model for each of the eight models. Similarly, Table
5.3 contains the estimates of the parameters of the survival part.
Observing the estimates of the ﬁxed eﬀect parameters in Table 5.2 we
see that they are quite similar. As already announced, the quadratic term is
practically null. Moreover, from the values of the estimates of the covariances
σ01 and σ12, we can see that those patients with a high intercept tend to have
an increasing trend, and that those with an increasing trend have a concave
trajectory.
1Both AIC and BIC are measures of the relative goodness of ﬁt of a statistical model.
They are used when we need to compare models that are not nested so that the classical
likelihood ratio test (LRT) cannot be applied. The AIC and BIC are deﬁned as
AIC = 2p − 2l(ˆ θ)
BIC = plog(N) − 2l(ˆ θ),
where −2l(ˆ θ) is the maximized log-likelihood under the ﬁtted model, ˆ θ is the maximum
likelihood estimate of θ, p is the number of parameters in the model, and N is the total
number of observations used to ﬁt the model (Wu 2010). When comparing diﬀerent
models, the model with the smaller AIC or BIC is to be preferred.
50Model name Parameterization
J1 current value
J2 current slope
J3 current value + current slope
J4 cumulative eﬀect
J5 weighted cumulative eﬀect
J6 lagged value
J7 lagged slope
J8 lagged value + lagged slope
Table 5.1: Model name and corresponding parameterization
Model Model Model Model Model Model Model Model
J1 J2 J3 J4 J5 J6 J7 J8
β0 0.515 0.451 0.500 0.512 0.514 0.516 0.485 0.509
(s.e.) (0.057) (0.043) (0.048) (0.058) 0.058 (0.058) (0.044) (0.053)
β1 0.167 0.172 0.180 0.164 0.162 0.164 0.197 0.186
(s.e.) (0.023) (0.019) (0.022) (0.023) (0.023) (0.022) (0.020) (0.023)
β2 0.001 0.003 0.001 0.001 0.001 0.001 0 0
(s.e.) (0.003) (0.002) (0.002) (0.003) (0.003) (0.003) (0.002) (0.003)
σ2
0 1.001 0.976 0.996 1.001 1.000 1.002 0.960 0.995
σ2
1 0.301 0.295 0.319 0.302 0.304 0.297 0.313 0.315
σ2
2 0.025 0.020 0.025 0.025 0.025 0.024 0.022 0.025
σ01 0.198 0.421 0.275 0.168 0.173 0.185 0.5067 0.286
σ02 0.002 0.019 -0.049 0.017 0.022 -0.004 -0.309 -0.091
σ12 -0.867 -0.739 -0.853 -0.883 -0.873 -0.880 -0.842 -0.869
σ2 0.303 0.311 0.303 0.305 0.304 0.306 0.311 0.304
Table 5.2: Parameter estimates of the longitudinal part of the eight joint
models
Considering the estimates of the survival part in Table 5.3, we notice
that all the parameters are highly signiﬁcant (p-value < 0.0001). This means
that serum bilirubin, independently of the parameterization used, is strongly
related with the risk for death. For example, according to model J1, each unit
increase of the current value of the covariate is associated with a exp(1.314)
= 3.72-fold increase (95% CI: 3.37; 4.11) in a patient’s risk. According to
model J8, being m
′
i(t − c) ﬁxed, each unit increase of the lagged value of
the covariate is associated with a exp(1.106) = 3.02-fold increase (95% CI:
2.72; 3.36) in the patient’s current risk. Similarly, being mi(t−c) ﬁxed, each
unit increase of the lagged slope is associated with a exp(3.740) = 42.10-fold
51Model Model Model Model Model Model Model Model
J1 J2 J3 J4 J5 J6 J7 J8
αj 1.314 7.241 1.237 0.184 2.435 1.216 6.943 1.106
(s.e.) (0.099) (0.777) (0.115) (0.020) (0.183) (0.092) (0.770) (0.106)
αj.s - - 3.006 - - - - 3.740
(s.e.) - - (0.624) - - - - (0.582)
log(ω1) -4.573 -5.620 -5.641 -2.907 -3.698 -4.026 -5.883 -5.313
(s.e.) (0.258) (0.433) (0.409) (0.155) (0.193) (0.217) (0.479) (0.380)
log(ω2) -4.429 -4.344 -5.211 -2.928 -3.954 -3.607 -4.448 -4.554
(s.e.) (0.274) (0.318) (0.361) (0.180) (0.236) (0.214) (0.334) (0.304)
log(ω3) -4.710 -4.360 -5.352 -3.456 -4.281 -3.960 -4.214 -4.752
(s.e.) (0.318) (0.329) (0.383) (0.257) (0.290) (0.273) (0.319) (0.331)
log(ω4) -4.672 -4.304 -5.257 -3.608 -4.266 -3.976 -3.991 -4.651
(s.e.) (0.370) (0.376) (0.424) (0.331) (0.347) (0.334) (0.354) (0.376)
log(ω5) -4.396 -4.198 -4.973 -3.533 -4.012 -3.748 -3.686 -4.313
(s.e.) (0.343) (0.356) (0.394) (0.315) (0.319) (0.306) (0.315) (0.342)
log(ω6) -4.021 -3.919 -4.729 -3.486 -3.633 -3.420 -3.310 -3.878
(s.e.) (0.353) (0.388) (0.431) (0.379) (0.329) (0.321) (0.333) (0.347)
log(ω7) -4.549 -3.865 -4.752 -5.162 -4.302 -4.235 -3.559 -4.318
(s.e.) (0.477) (0.478) (0.507) (0.605) (0.463) (0.459) (0.450) (0.472)
Table 5.3: Parameter estimates of the survival part of the eight joint models
increase (95% CI: 23.52; 75.34) in the patient’s current risk. Interestingly,
comparing the estimates of α1 and α6 with those of α3 and α8, we see that
the latter are slightly smaller that the former. This suggests that indeed the
trajectory slope adds some information in the model, however, the covariate
value still keeps its importance. The small value of the parameter α4 should
be kept in mind since it will have an important role in understanding the
peculiar behavior characterizing the diﬀerences between model J1 and model
J2 survival predictions.
5.4 Expected survival probabilities compari-
son
For each of the eight models, we computed the following expected survival
probabilities (ESPs), which we remind are conditional probabilities: S(t +
∆t | t), where t = 2,4,6,8 years and ∆t = 1,2,4 years. Comparing the ESPs
of the eight considered models we found that, indeed, there are diﬀerences
which can be attributed to the speciﬁc association structure assumed in the
survival sub-model. The ESPs are obtained using the estimator deﬁned by
(4.7). Conclusions would not have changed if we had used the estimator
52deﬁned by (4.6).
We compared the ESPs of the standard joint model, i.e. model J1, with
those of the other seven models. The number of comparisons that can be
made is rather high: there are 12 types of S(t+∆t | t), and 7 ESP comparisons
for each of them. Thus, in total, we analysed 84 comparisons. We noticed
that the reasoning behind the 7 ESP comparisons for one type of S(t+∆t | t)
is also applicable in the other 11 cases. Thus, we have chosen to concentrate
our attention on S(4 | 2). Our choice is base on the fact that, at year 2, the
majority of the patients are still alive and uncensored. Moreover, a ∆t equal
to 2 gives enough time to the ESPs to decrease and thus leave the usually
high values typical of time points immediately after t. We remind, indeed,
that, independently of the risk level of the patient and of the model, ESPs
at time t are always equal to 1 and then start to decrease with a rate which
depends on the risk level attribute to the patient by the model. This ﬁrst
part of the analysis will be discussed in detail in Section 5.4.1. We will show
how diﬀerent association structures substantially change survival predictions
using S(4 | 2) as example.
In Section 5.4.2, we will consider another aspect charaterizing the diﬀer-
ences between ESPs. Concentrating on only those patients who were still
alive and uncensored at year 6, we will show how the diﬀerence between the
ESP of model J1 with respect to that of the other seven models can change
as ∆t increases.
For ease of exposition, the expected survival probability estimated by
model Ji, i = 1,...,8, will be indicated with ESPi. For example, the ESP
computed by model J1 will be indicated with ESP1.
Finally, before starting with the description of our ﬁndings, we wish to
point out one aspect that characterizes the longitudinal part of the models we
are considering here. At the end of Chapter 4, we mentioned that the values
of the parameters deﬁning the longitudinal trajectory diﬀer from model to
model. Observing the trajectories predicted by model J1 with those predicted
by the other models, we noticed that the ‘biggest’ diﬀerences belong to model
53J2. The ﬁrst row of Figure 1 contains the trajectories for patients 180, 133,
and 93 based on the serum bilirubin measurements collected in the ﬁrst 2
years of study. Likewise, those plotted in the second row are based on the
measurements collected in the ﬁrst 6 years. Each plot contains the trajectory
predicted by model J1 (solid line) and by model J2 (dashed line). Usually,
the diﬀerences between the two curves become more evident in later years.
Moreover, the addiction of new bilirubin values does not always guarantee a
reduction of these diﬀerences (for instance, compare the plots of patient 133).
Also the curves predicted by model J7 are sometimes diﬀerent from those of
model J1, but are closer to them than those predicted by model J2 (results
not shown). About the other models, their curves are, if not coincident, very
close to those of model J1 so that the diﬀerences are imperceptible. Having
said that, in order to correctly understand the mechanism underlying the
possible diﬀerences between ESP1 and ESP2, it is important to have both
the curve predicted by model J1 and the one predicted by model J2. This
would also help the comparison of ESP2s among diﬀerent patients.
5.4.1 Comparing ESPs for S(4 | 2)
The probability of surviving year 4, given survival up to year 2, is computed
only for those patients who were still in the study at year 2. These patients
were 278 (89%) of the 312 study participants. Between year 2 and year 4,
53 patients dropped out from the study: 42 actually died whereas 11 were
censored.
ESP1 vs ESP2
The left plot of Figure 5.2 shows the scatter plot of the ESP1 (x-axis) and
ESP2 (y-axis). We see that the disagreement is more evident for those pa-
tients with a low ESP value. For these patients, model J1 tends to be more
pessimist than model J2. The departure from the 1:1 line is due to the 43
patients with diﬀerence between ESP1 and ESP2 lower than -0.10. These
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Figure 5.1: Observed log(serBilir) values (black circles) and longitudinal
trajectories predicted by model J1 (solid line) and model J2 (dashed line).
The trajectories of the ﬁrst row are based on the measurements collected in
the ﬁrst 2 years of study whereas those in the second row on the measure-
ments collected in the ﬁrst 6 years.
patients are usually characterized by high serum bilirubin levels at baseline
and low slopes. Thus, for model J1, these patients are high risk patients
while for model J2 are low risk patients. A clear example is given in Figure
5.3 and Table 5.4. Patient 130 presents high covariate levels from the begin-
ning of the study whereas patients 205 and 51 have much lower initial values.
The slopes of patients 130 and 205 are slightly increasing over time whereas
the slope of patient 50 is markedly decreasing. Since model J2 considers only
the trajectory’s slope, the ESP2 of patient 130 is very high in comparison to
the corresponding ESP1. On the other hand, model J1 and model J2 agree
on patient 205: the covariate initial levels are above 1 and the slope is not
ignorable so that both models predict a slight worsening of patient’s health
conditions between year 2 and year 4. Finally, patient 50 is characterized by
55rather low initial covariate values and this strongly aﬀects model J1’s judge-
ment: there is a 90% chance of surviving up to year 4, given that patient 50
survived year 2.
If ESP1 seems not to be so inﬂuenced by the rapid increment of the
covariate over time, ESP2 does not ignore it. In this case, model J2 is more
pessimist than model J1 because of the high, although decreasing, slope. The
histogram in Figure 1 shows that most of the diﬀerences (66.5%) between
ESP1 and ESP2 are contained in the interval [0,1) and the 88.6% of them
are smaller than 0.05. The scatter plot nearby displays a tenuous curvature
of the loess curve towards positive values for ESPs closed to 1. These little
positive diﬀerences belong to patients with low covariate values, mostly below
1, and a weak increasing trend. This last feature causes model J2 to be a
little more pessimist than model J1.
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Figure 5.2: Scatter plot of ESP1 and ESP2 and histogram of ESP1-ESP2
56Subject ESP1 ESP2 ESP1-ESP2
130 0.31 0.70 0.39
205 0.83 0.84 0.01
51 0.90 0.76 0.14
Table 5.4: Comparison of ESP1 and ESP2 for three patients
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Figure 5.3: Longitudinal trajectories predicted by model J1 (solid line) and
model J2 (dashed line), and observed log(serBilir) (black circles)
57ESP1 vs ESP3
The 95% of the diﬀerences between ESP1 and ESP3 belong to the interval
[−0.10,0.10) meaning that model J1 and model J3 produce very close sur-
vival predictions (see Figure 5.4). Patients 156, 260 and 90 can help us to
understand what happens when the information from the slope is added to
that from the current value. The results are presented in Table 5.5 and Figure
5.5. The covariate trajectory of patient 156 is characterized by covariate val-
ues which are already high at the beginning of the study and slightly increase
over time. The very optimistic prediction made by model J2 is corrected by
model J3. Patient 260 presents a better health condition in comparison to
patient 156, however, the reasoning is the same. On the contrary, model J3
is more pessimist about the future of patient 90 than are models J1 and J2.
Model J3, in fact, combines the eﬀect of the covariate value, which becomes
higher than 2 between year 2 and 4, with that of a slope which, although
decreasing, is still highly positive.
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Figure 5.4: Scatter plot of ESP1 and ESP3 and histogram of ESP1-ESP3
58Subject ESP1 ESP2 ESP3 ESP1-ESP3
156 0.13 0.70 0.28 -0.15
260 0.60 0.75 0.64 -0.04
90 0.62 0.55 0.49 0.13
Table 5.5: Comparison of ESP1, ESP2 and ESP3 for three patients
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Figure 5.5: Longitudinal trajectories predicted by model J1 (solid line) and
model J3 (dashed line), and observed log(serBilir) (black circles)
59ESP1 vs ESP4
74% of the diﬀerences between ESP1 and ESP4 belong to the interval [0,0.10)
while the remaining 26% is below zero. Again, the more evident diﬀerences
belong to patients with the lowest survival probabilities, but, as it can be seen
in the scatter plot of Figure 5.6, the dispersion around the 1:1 is rather small.
In this case, two may be the reasons behind this behaviour. First, all the
integrals start from zero independently of the covariate trajectory’s features
and the integral tends to homogenize the trajectory diﬀerences, especially in
the very ﬁrst years of study when trajectories are more similar. Second, the
value of association parameter α4 is not that high (α4 = 0.181) so that a
substantial increase of the integral value is needed in order to signiﬁcantly
augment the value of the risk function. For example, in order to obtain the
same risk’s increment given by one unit increase of the covariate value, the
integral increment should be equal to 7.141, which is a lot for the types of
longitudinal trajectories considered here. The consequences are not univocal
for all patients. More speciﬁcally, they can be divided into two groups: to
the ﬁrst group belong 207 patients with a EPS1 higher than or equal to
0.794, all the other 71 patients belong to the second group, where ESP1 is
lower than 0.794. The ﬁrst group generates the tenuous deviation on the
right of the loess curve from the 1:1 line in the scatter plot of Figure 5.6.
Similarly, the negative diﬀerences of the second group generate the prominent
deviation towards the left and this deviation increases as ESP1 decreases.
The maximum diﬀerence between ESP1 and ESP4 is equal to -0.489.
We use patients 25, 54, and 80 as examples (see Table 5.6 and Figure
5.7). ESP1 is slightly more optimist than model J4. This is probably due
to the fact that the baseline hazard function h0(t) of model J4 is slightly
higher than that of model J1 and to the small value of the parameter α4
which makes the negative integral to be less ‘protective’ than the negative
covariate value. In patient 54, a consistent increasing integral value and a
covariate value which starts around 0.5 and do not reach 2 within year 4
makes the two ESPs to practically agree. On the contrary, the rather high
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Figure 5.6: Scatter plot of ESP1 and ESP4 and histogram of ESP1-ESP4
initial covariate value of patient 80 and its increment over time makes ESP1
decrease more quickly than does the corresponding increment of the integral
with respect to ESP4.
Subject ESP1 ESP4 ESP1-ESP4
25 0.98 0.92 0.05
54 0.84 0.83 0.01
80 0.37 0.63 -0.26
Table 5.6: Comparison of ESP1 and ESP4 for three patients
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Figure 5.7: Longitudinal trajectories predicted by model J1 (solid line) and
model J4 (dashed line), and observed log(serBilir) (black circles)
62ESP1 vs ESP5
Maybe surprisingly, using a weighted cumulative eﬀect greatly reduces the
observed gap between ESP1 and ESP4. All the diﬀerences belong to the
interval [−0.10,0.10] (see Figure 5.8). Evidently, model J1 and model J5, al-
though using a diﬀerent version of the information contained in the covariate,
reach very close conclusions.
The weighted integral has a much greater inﬂuence on the risk function
of model J5 that does the normal integral on that of model J4: while α4 is
equal to 0.184, α5 is equal to 2.435. This means that a one unit increase of
the normal integral is associated with a exp(0.184) = 1.20-fold increase in the
patient’s risk, whereas a one unit increase of the weighted integral produces
a exp(2.435) = 11.42-fold increase in the patient’s risk.
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Figure 5.8: Scatter plot of ESP1 and ESP5 and histogram of ESP1-ESP5
ESP1 vs ESP6
253 (91%) of the diﬀerences between ESP1 and ESP6 belong to the inter-
val [−0.10,0.10) and 226 (81.3%) are contained in the interval [−0.05,0.05).
Only 25 (9%) patients have an absolute diﬀerence higher than 0.10. This
time, there is not a very evident pattern that could explain a negative in-
stead of a positive diﬀerence. We see that model J1 tends to be slightly
63more optimist than model J2 with low risk patients (Figure 5.9). In fact,
considering the 188 individuals with a diﬀerence in the interval [0, 0.05), 165
(87.8%) of them have a ESP1 higher than 0.90, 13 (6.9%) have a ESP1 be-
tween 0.80 and 0.90 and the other 10 (5.3%) have a ESP1 lower than 0.80.
In general, diﬀerences belonging to the interval [-0.10, 0.10] can be ascribable
to the fact that the quantities ESP1 and ESP6 are based on models using
slightly diﬀerent baseline hazard functions (the estimated baseline hazard of
model J6 is higher than that of model J1) and longitudinal models, and only
marginally to trajectories’ characteristics which are practically constant in
the ﬁrst four years of study.
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Figure 5.9: Scatter plot of ESP1 and ESP6 and histogram of ESP1-ESP6
For those diﬀerences not belonging to that interval, we notice a possible
stronger inﬂuence of the diﬀerent use of the covariate information made by
the two models. For example, patients 254 and 269 have the biggest positive
and negative diﬀerences (Figure 5.10 and Table 5.7). Their longitudinal
trajectories are characterized by moderate initial values of the covariate and
quite high slopes. Since, with high and increasing covariate values, the risk
increases more quickly and model J6 considers lagged values, ESP1 is lower
than ESP2. On the contrary, patients 93 and 130 do present a covariate
64increment which is smaller than that of the previous two patients so that
both models predict similar ESPs.
Subject ESP1 ESP6 ESP1-ESP6
254 0.23 0.44 -0.21
269 0.16 0.37 -0.21
93 0.80 0.84 -0.84
130 0.31 0.27 0.04
Table 5.7: Comparison of ESP1 and ESP6 for four patients
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Figure 5.10: Longitudinal trajectories predicted by model J1 (solid line) and
model J4 (dashed line), and observed log(serBilir) (black circles)
65ESP1 vs ESP7
225 (80.9%) are the patients with a diﬀerence between ESP1 and ESP7 in
the interval [-0.10, 0.10) whereas 43 (15.5%) patients have diﬀerences be-
longing to the interval (-0.70, -0.20). These patients are the same individuals
which were pointed out in the comparison between the ESPs of model J1
and model J2: their trajectories are mostly characterized by high covariate
initial values and slopes, which are constant or slightly decreasing. However,
the diﬀerences observed in this case tend to be more accentuated. In fact,
comparing the scatter plots in Figure 5.2 and Figure 5.11 we can see that
the loess function in the latter plot tends to stay higher.
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Figure 5.11: Scatter plot of ESP1 and ESP7 and histogram of ESP1-ESP7
As we have noticed before, the information given by the slope, and in this
case the lagged slope, can result in quite diﬀerent expected survival proba-
bilities with respect to the information given by the current value. Table
5.8 and Figure 5.12 give a further example. According to model J7, patients
156, 130, 241, and 214 have practically the same probability of surviving
year 4 given that they were alive at year 2: ESP7 is equal to 0.82 for patients
156 and 241, while it is equal to 0.81 for patients 130 and 214. However,
model J1 rather disagrees: the ESP1s are equal to 0.13, 0.66, 0.31 and 0.90,
66respectively. The reason is made clearer looking at the covariate trajectories
in Figure 5.12 ﬁtted according to model J7. Indeed, patients 156, 241, and
214 have the same (lagged) slope in practice, and this explains the practi-
cally equal ESP7s. On the contrary, their trajectories are quite diﬀerent in
the starting values and this strongly aﬀects the ESPs of model J1: since pa-
tient 156 has the highest starting value, his/her survival probability is very
low, whereas patient 214, with a starting value close to zero, has the highest
survival probability.
Subject ESP1 ESP7 ESP1-ESP7
156 0.13 0.82 -0.69
130 0.31 0.81 -0.50
241 0.66 0.82 -0.16
214 0.90 0.81 0.09
Table 5.8: Comparison of ESP1 and ESP7 for four patients
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Figure 5.12: Longitudinal trajectories predicted by model J7 of patients 156
(solid line), 130 (dashed line), 241 (dotted line), and 214 (dashed and dotted
line)
67ESP1 vs ESP8
Model J8 uses the information from both the lagged value and the lagged
slope so that the discrepancies seen in the previous comparison are greatly
reduced (see Figure 5.13). 262 (94.2%) diﬀerences are in the interval [-0.10,
0.10), with 241 (86.7%) being in the interval [-0.05, 0.05). The 16 (5.8%)
absolute diﬀerences which are higher than 0.10, belong to the same high risk
patients pointed out in the previous comparisons. The information brought
into the model by the lagged covariate value makes model J8 to be less
optimist than model J7 for those patients.
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Figure 5.13: Scatter plot of ESP1 and ESP8 and histogram of their diﬀerence
Table 5.9 reports the ESPs of model J1 and model J8 for the four patients
already considered in Table 5.8. In particular, the diﬀerence between ESP1
and ESP8 is about -0.20 for both patients 156 and 130, whereas the diﬀerence
between ESP1 and ESP7 was -0.69 for patient 156 and -0.50 for patient 130.
68Subject ESP1 ESP8 ESP1-ESP8
156 0.13 0.32 -0.19
130 0.31 0.51 -0.20
241 0.66 0.69 -0.03
214 0.90 0.89 0.01
Table 5.9: Comparison of ESP1 and ESP8 for four patients
695.4.2 The time interval eﬀect on ESPs diﬀerences
In this part of the analysis, we wish to monitor the changes in the ESP
diﬀerences when ∆t increases. This time, we are going to use only those
patients who survived at least 6 years. In fact, for these patients the number
of serum bilirubin measurements used to estimate the longitudinal part of
the model is higher so that the longitudinal trajectories will be closer to the
‘true’ ﬁnal trajectories, which are those obtained using all the measurement
values actually available at the end of the study. For example, in Figure
5.14, the longitudinal trajectories of patients 96 and 142 are shown. The
trajectories of the ﬁrst and the second row are based on the measurements
available at year 2 and 6, respectively. Since the measurements of patient 96
are nearly constant between year 2 and year 6, the trajectories are practically
the same. On the contrary, patient 142 presents an increasing trend which
makes his/her trajectory at year 6 steeper than that at year 2. The eﬀect on
the predicted trajectory when new measurent are available can be also seen
in Figure 5.1.
The number of patients involved in this analysis are 166 (53%). It should
always be kept in mind that these patients are a selected group of all the 312
patient participating to the study. More speciﬁcally, the major part of those
patients who were already at high risk at year 2 (according to model J1) did
not survived until year 6. Consequently, most of the 166 patients considered
now had a low or moderate risk of death at year 2. Their risk level at year
6 depends on the serum bilirubin evolution between year 2 and year 6.
In the following part, we will show how diﬀerences between the ESPs pre-
dicted by model J1 and the other models as the time interval ∆t increases.
For each comparison, we will report a ﬁgure containing the ESPs’ scatter
plots for S(7 | 6), S(8 | 6) and S(10 | 6), a table containing the ESPs for
S(7 | 6), S(8 | 6) and S(10 | 6) and the respective diﬀerences, and a ﬁg-
ure which will represent these diﬀerences. In order to give more speciﬁc
examples, we will use 20 patients whose covariate trajectories are considered
‘representative’ of the diﬀerent trajectory types characterizing the 166 pa-
70tients involved in the analysis. The identiﬁcation numbers of the selected
patients are: 135, 218, 19, 96, 34, 48, 136, 99, 258, 166, 39, 161, 133, 85,
180, 104, 46, 142, 51, 93. Patients are listed according to their ESP1 value
for S(7 | 6) in a descending order. Figures from 5.15 to 5.19 contain the
predicted trajectories of the 20 selected patients ﬁtted according to model J1
(solid line) and model J2 (dashed line).
For practical reasons, the diﬀerences between ESP1 and ESPj, j =
2,...,8, will be indicated with DIFF1j. Moreover, in general, when we will
describe DIFF1j, we will mean its absolute value. For example, if we say
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Figure 5.14: Longitudinal trajectories predicted by model J1 (solid line)
and model J2 (dashed line) at year 2 (ﬁrst row). Longitudinal trajectories
predicted by model J1 (solid line) and model J2 (dashed line) at year 6
(second row)
71that DIFF1j is increasing over time it could either be that DIFF1j was -0.05
and becomes -0.20 or that diﬀ1j was 0.05 and becomes 0.20. The context or
explicit indications will clarify in which case we are.
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Figure 5.15: Longitudinal trajectories predicted by model J1 (solid line) and
model J2 (dashed line), and observed log(serBilir) (black circles)
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Figure 5.16: Longitudinal trajectories predicted by model J1 (solid line) and
model J2 (dashed line), and observed log(serBilir) (black circles)
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Figure 5.17: Longitudinal trajectories predicted by model J1 (solid line) and
model J2 (dashed line), and observed log(serBilir) (black circles)
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Figure 5.18: Longitudinal trajectories predicted by model J1 (solid line) and
model J2 (dashed line), and observed log(serBilir) (black circles)
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Figure 5.19: Longitudinal trajectories predicted by model J1 (solid line) and
model J2 (dashed line), and observed log(serBilir) (black circles)
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Figure 5.20: Scatter plots of ESP1 and ESP2 for S(7 | 6), S(8 | 6), and
S(10 | 6)
As it can be seen in Figure 5.20, as ∆t increases, the diﬀerences between
ESP1 and ESP2 tends to increase, however the pattern is not equal for all
patients. In fact, Figure 5.21 and Table 5.10 show that model J1 tends to be
more optimist than model J2 for patients with the highest S(7 | 6) values (i.e.
patients on the left of Figure 5.21). On the contrary, model J1 is more pes-
simist than model J2 for those patients with the lowest S(7 | 6) (i.e. patients
on the right of Figure 5.21). We give some examples. Patients 19, 96 and 34
have the biggest (positive) diﬀerences since their covariate values tends to
stay below 0 for several years after the study entry, and then start to slowly
increase. Model J2 is particularly sensitive to this increment while model J1,
since the current covariate values are still low, is more positive. Models J1
and J2 substantially agree on the ESPs of patients 99 and 258: their slope
is not ignorable and their covariate values are above zero. Patients 93, 51,
and 142 have the biggest (negative) diﬀerences: ESP2 does not decrease as
fast as ESP1 so that the DIFF12 increases over time. The fast decrement
of ESP1 is attributable to the quite high covariate values which characterize
patients’ trajectories, especially between year 6 and year 10. On the other
77hand, model J2 sees a current slope which is decreasing in that interval. On
the contrary, patients 46 have a high and increasing current slopes which
makes DIFF12 decrease over time.
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Figure 5.21: DIFF12 for S(7 | 6) [circle], S(8 | 6) [square], and S(10 | 6)
[triangle]
Now, we wish to focus our attention on two groups of patients. In the
ﬁrst group we have patients 161, 133, 85, 180, and 104. In the second we
have patients 142, 51, 93. We see that DIFF12 at year 8 and DIFF12 at year
10 are more far apart in the ﬁrst group than in the second (see Figure 5.21).
In particular, what happen to patient 93 is emblematic: DIFF12 decreases
between year 8 and 10. We call this the low-ESP eﬀect and it can be well
understood looking at Figure 5.22 and Table 5.10. The ESP1 of patient 93
at year 8 is already very low (i.e. ESP1 = 0.095). The consequence is that
ESP1 will not decrease much further during the subsequent 2 years since
ESPs have zero as lower boundary. On the contrary, ESP2 at year 8 is equal
to 0.618 so that it can signiﬁcantly decrease, shortening the gap with ESP1.
Conversely, patient 104 has a higher ESP1 at year 8 than patient 93 and thus
his/her DIFF12 is immune to the low-ESP eﬀect.
78S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP2 DIFF12 ESP1 ESP2 DIFF12 ESP1 ESP2 DIFF12
135 0.996 0.981 0.015 0.991 0.955 0.036 0.973 0.872 0.101
218 0.995 0.974 0.021 0.989 0.940 0.049 0.965 0.839 0.126
19 0.995 0.958 0.037 0.986 0.895 0.091 0.944 0.711 0.233
96 0.992 0.962 0.030 0.980 0.907 0.073 0.925 0.751 0.174
34 0.984 0.933 0.051 0.958 0.846 0.112 0.842 0.647 0.195
48 0.980 0.963 0.017 0.950 0.911 0.039 0.838 0.756 0.082
136 0.975 0.953 0.022 0.938 0.897 0.041 0.809 0.757 0.052
99 0.975 0.955 0.020 0.935 0.896 0.039 0.767 0.722 0.045
258 0.963 0.931 0.032 0.906 0.853 0.053 0.718 0.688 0.030
166 0.962 0.868 0.094 0.881 0.675 0.206 0.457 0.297 0.160
39 0.951 0.853 0.098 0.851 0.716 0.135 0.470 0.485 -0.015
161 0.890 0.952 -0.062 0.754 0.897 -0.143 0.477 0.780 -0.303
133 0.878 0.935 -0.057 0.725 0.871 -0.146 0.421 0.746 -0.325
85 0.866 0.862 0.004 0.659 0.711 -0.052 0.214 0.431 -0.217
180 0.789 0.870 -0.081 0.547 0.720 -0.173 0.174 0.447 -0.273
104 0.755 0.813 -0.058 0.461 0.674 -0.213 0.114 0.488 -0.374
46 0.726 0.737 -0.011 0.378 0.491 -0.113 0.038 0.177 -0.139
142 0.617 0.824 -0.207 0.298 0.700 -0.402 0.066 0.546 -0.480
51 0.548 0.833 -0.285 0.235 0.729 -0.494 0.048 0.611 -0.563
93 0.370 0.768 -0.398 0.095 0.618 -0.523 0.006 0.450 -0.444
Table 5.10: Comparison of ESP1, ESP2, and DIFF12 over time
0
.
0
0
.
4
0
.
8
Subject 104
Time
P
r
(
T
i
³
u
 
|
 
T
i
>
t
,
y
~
i
(
t
)
)
0 2 4 6 8 10 12
0
.
0
0
.
4
0
.
8
Subject 104
Time
P
r
(
T
i
³
u
 
|
 
T
i
>
t
,
y
~
i
(
t
)
)
0 2 4 6 8 10 12
0
.
0
0
.
4
0
.
8
Subject 93
Time
P
r
(
T
i
³
u
 
|
 
T
i
>
t
,
y
~
i
(
t
)
)
0 2 4 6 8 10 12
0
.
0
0
.
4
0
.
8
Subject 93
Time
P
r
(
T
i
³
u
 
|
 
T
i
>
t
,
y
~
i
(
t
)
)
0 2 4 6 8 10 12
Figure 5.22: Comparison of ESP1 (ﬁrst column) and ESP2 (second column)
of two patients. The solid line depicts the mean of πi(u | t) over the Monte
Carlo samples. The dashed line depicts a 95% pointwise conﬁdence intervals
based on the quantiles of πi(u | t) over the Monte Carlo samples.
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Figure 5.23: Scatter plots of ESP1 and ESP3 for S(7 | 6), S(8 | 6), and
S(10 | 6)
Model J1 and J3 tend to give closer ESPs than model J2 as we can see
from Figure 5.23 and Figure 5.24. In general, from Figure 5.24, we can see
that diﬀerences start to reach consistent values when ∆t = 4. In fact, when
∆ = 1, ∆t = 2, and ∆t = 4 there are , respectively, 3, 9, and 24 diﬀerences
which are bigger than 0.10 (but smaller than 0.20). The highest negative
diﬀerences belong to patients with a longitudinal trajectory similar to that
of patients 161 and 51: their slopes are small and decreasing between year
6 and 10 so that model J3 tends to be more optimist. The inﬂuence of an
increasing slope on ESP3 is made quite evident if we consider patient 46 and
166: both their trajectories have a strongly increasing slope after year 4 but
patient 46 has much higher initial covariate values. First we analyse patient
46. DIFF13 at year 7 is equal to 0.143 so that model J1 is more optimist than
model J3 which is inﬂuenced by the high value of the current slope. Between
year 7 and 8, DIFF13 stays constant in practice but between year 8 and 10
strongly decreases so that, at year 10, it is nearly zero. We remind that in
model J1, the current covariate value has more weight than in model J3,
thus the high covariate values between year 8 and 10 allow ESP1 to decrease
80more quickly than ESP3 and reach similar values. Now we analyse patient
166. At year 7, ESP3 is only slightly lower than ESP1. However, in this case,
ESP3 will decrease more rapidly than ESP1 since patient’s covariate value
exceeds 2 only after year 8.
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Figure 5.24: DIFF13 for S(7 | 6) [circle], S(8 | 6) [square], and S(10 | 6)
[triangle]
81S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP3 DIFF13 ESP1 ESP3 DIFF13 ESP1 ESP3 DIFF13
135 0.996 0.996 0 0.991 0.989 0.002 0.973 0.944 0.029
218 0.995 0.996 -0.001 0.989 0.989 0 0.965 0.960 0.005
19 0.995 0.994 0.001 0.986 0.983 0.003 0.944 0.910 0.034
96 0.992 0.992 0 0.980 0.976 0.004 0.925 0.884 0.041
34 0.984 0.980 0.004 0.958 0.943 0.015 0.842 0.774 0.068
48 0.980 0.984 -0.004 0.950 0.958 -0.008 0.838 0.849 -0.011
136 0.975 0.975 0 0.938 0.931 0.007 0.809 0.786 0.023
99 0.975 0.981 -0.006 0.935 0.949 -0.014 0.767 0.821 -0.054
258 0.963 0.960 0.003 0.906 0.894 0.012 0.718 0.677 0.041
166 0.962 0.917 0.045 0.881 0.726 0.155 0.457 0.284 0.173
39 0.951 0.916 0.035 0.851 0.760 0.091 0.470 0.374 0.096
161 0.890 0.924 -0.034 0.754 0.828 -0.074 0.477 0.627 -0.15
133 0.878 0.901 -0.023 0.725 0.781 -0.056 0.421 0.566 -0.145
85 0.866 0.807 0.059 0.659 0.564 0.095 0.214 0.234 -0.020
180 0.789 0.755 0.034 0.547 0.487 0.060 0.174 0.195 -0.021
104 0.755 0.713 0.042 0.461 0.474 -0.013 0.114 0.241 -0.127
46 0.726 0.583 0.143 0.378 0.235 0.143 0.038 0.033 0.005
142 0.617 0.628 -0.011 0.298 0.394 -0.096 0.066 0.189 -0.123
51 0.548 0.613 -0.065 0.235 0.382 -0.147 0.048 0.224 -0.176
93 0.370 0.436 -0.066 0.095 0.197 -0.102 0.006 0.071 -0.065
Table 5.11: Comparison of ESP1, ESP3, and DIFF13 over time
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Figure 5.25: Scatter plots of ESP1 and ESP4 for S(7 | 6), S(8 | 6), and
S(10 | 6)
From Figure 5.25 we can see that, also in this case, the biggest diﬀerences
belong to medium and high risk patients, with model J1 being, in general,
more pessimist than model J4.
Figure 5.26 and Table 5.12, however, show that high diﬀerences at year
7 tend to decrease as time passes and to be particularly close to zero at
year 10. On the other hand, several diﬀerences which were small at year
7, tend to increase as time passes. To the ﬁrst group belong patients 51,
93, 142, and 104. Their trajectories are characterized by covariate values
close to zero at the beginning of the study and a rapid increase over time
which makes them reach very high covariate values, especially between year
6 and 10. A consequence is that the value of the integral increases a lot in
four years thus making ESP4 decrease rapidly. To the second group belong
patients 39, 166, and 161. Patients 39 and 166 have covariate values which
stay below one at least until year 6 and then start to rapidly increase. On
the contrary, patient 161 has covariate values which are slightly above one
at the beginning of the study and are not expected to exceed two in the
following years. The reduction of the gap between ESP1 and ESP4 among
83patients of the ﬁrst group is attributable to both the rapid increment of the
integral after year 6 and to the low-ESP eﬀect. Figure 5.27 shows it quite
clearly. Indeed, considering patient 104, DIFF16 decreases over time but is
still bigger than 0.10 since his/her ESP1 at year 7 and 8 is still high (i.e.
ESP1 = 0.755 and ESP1 = 0.461 respectively, see Table 5.12). Thus, ESP1
can signiﬁcantly decrease and be still lower than ESP6. On the contrary,
ESP1 at year 7, but especially at year 8, are already low (i.e. ESP1 = 0.37
and ESP1 = 0.095, respectively) so that it cannot decrease much further.
Therefore, ESP6 has the opportunity to reach ESP1. For patients 39 and
166, DIFF14 is increasing over time since their integrals are still small at
year 6 and, although increasing, ESP6 does not decrease as fast as ESP1.
On the other hand, the reasoning behind patient 161 is slightly diﬀerent.
ESP6 decreases more quickly than ESP1 since integral at year 6 is already
consistent and keeps increasing signiﬁcantly. On the contrary, ESP1 tends to
decrease slowly since the covariate value is not that high and the increment
between year 6 and 10 is truly small.
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Figure 5.26: DIFF14 for S(7 | 6) [circle], S(8 | 6) [square], and S(10 | 6)
[triangle]
84S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP4 DIFF14 ESP1 ESP4 DIFF14 ESP1 ESP4 DIFF14
135 0.996 0.988 0.008 0.991 0.976 0.015 0.973 0.955 0.018
218 0.995 0.987 0.008 0.989 0.974 0.015 0.965 0.949 0.016
19 0.995 0.987 0.008 0.986 0.975 0.011 0.944 0.952 -0.008
96 0.992 0.981 0.011 0.980 0.961 0.019 0.925 0.921 0.004
34 0.984 0.974 0.010 0.958 0.945 0.013 0.842 0.876 -0.034
48 0.980 0.950 0.030 0.950 0.895 0.055 0.838 0.769 0.069
136 0.975 0.960 0.015 0.938 0.914 0.024 0.809 0.800 0.009
99 0.975 0.956 0.019 0.935 0.905 0.030 0.767 0.783 -0.016
258 0.963 0.950 0.013 0.906 0.888 0.018 0.718 0.727 -0.009
166 0.962 0.949 0.013 0.881 0.887 -0.006 0.457 0.709 -0.252
39 0.951 0.966 -0.015 0.851 0.924 -0.073 0.470 0.792 -0.322
161 0.890 0.837 0.053 0.754 0.642 0.112 0.477 0.254 0.223
133 0.878 0.875 0.003 0.725 0.717 0.008 0.421 0.346 0.075
85 0.866 0.850 0.016 0.659 0.662 -0.003 0.214 0.248 -0.034
180 0.789 0.758 0.031 0.547 0.486 0.061 0.174 0.091 0.083
104 0.755 0.887 -0.132 0.461 0.727 -0.266 0.114 0.306 -0.192
46 0.726 0.781 -0.055 0.378 0.508 -0.130 0.038 0.067 -0.029
142 0.617 0.825 -0.208 0.298 0.582 -0.284 0.066 0.120 -0.054
51 0.548 0.791 -0.243 0.235 0.510 -0.275 0.048 0.070 -0.022
93 0.370 0.668 -0.298 0.095 0.309 -0.214 0.006 0.011 -0.005
Table 5.12: Comparison of ESP1, ESP4, and DIFF14 over time
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Figure 5.27: Comparison of ESP1 (ﬁrst column) and ESP4 (second column)
of two patients. The solid line depicts the mean of πi(u | t) over the Monte
Carlo samples. The dashed line depicts a 95% pointwise conﬁdence intervals
based on the quantiles of πi(u | t) over the Monte Carlo samples.
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Figure 5.28: Scatter plots of ESP1 and ESP2 for S(7 | 6), S(8 | 6), and
S(10 | 6)
Figure 5.28 shows that model J1 and model J5, although using the covari-
ate information in a diﬀerent way, they do predict very similar ESP values.
We report Figure 5.29 and Table 5.13 for completeness.
S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP5 DIFF15 ESP1 ESP5 DIFF15 ESP1 ESP5 DIFF15
135 0.996 0.994 0.002 0.991 0.988 0.003 0.973 0.963 0.010
218 0.995 0.993 0.002 0.989 0.982 0.007 0.965 0.953 0.012
19 0.995 0.993 0.002 0.986 0.984 0.002 0.944 0.937 0.007
96 0.992 0.989 0.003 0.980 0.974 0.006 0.925 0.918 0.007
34 0.984 0.982 0.002 0.958 0.950 0.008 0.842 0.858 -0.016
48 0.980 0.974 0.006 0.950 0.938 0.012 0.838 0.826 0.012
136 0.975 0.969 0.006 0.938 0.928 0.010 0.809 0.778 0.031
99 0.975 0.970 0.005 0.935 0.937 -0.002 0.767 0.766 0.001
258 0.963 0.958 0.005 0.906 0.901 0.005 0.718 0.703 0.015
166 0.962 0.962 0 0.881 0.907 -0.026 0.457 0.566 -0.109
39 0.951 0.961 -0.01 0.851 0.875 -0.024 0.470 0.592 -0.122
161 0.890 0.876 0.014 0.754 0.753 0.001 0.477 0.429 0.048
133 0.878 0.878 0 0.725 0.740 -0.015 0.421 0.399 0.022
85 0.866 0.873 -0.007 0.659 0.705 -0.046 0.214 0.241 -0.027
180 0.789 0.801 -0.012 0.547 0.577 -0.003 0.174 0.182 -0.008
104 0.755 0.801 -0.046 0.461 0.561 -0.100 0.114 0.132 -0.018
46 0.726 0.772 -0.046 0.378 0.457 -0.079 0.038 0.058 -0.02
142 0.617 0.685 -0.068 0.298 0.422 -0.124 0.066 0.064 0.002
51 0.548 0.627 -0.079 0.235 0.320 -0.085 0.048 0.051 -0.003
93 0.370 0.483 -0.113 0.095 0.159 -0.064 0.006 0.007 -0.001
Table 5.13: Comparison of ESP1, ESP5, and DIFF15 over time
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Figure 5.29: DIFF15 for S(7 | 6) [circle], S(8 | 6) [square], and S(10 | 6)
[triangle]
87ESP1 vs ESP6
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Figure 5.30: Scatter plots of ESP1 and ESP2 for S(7 | 6), S(8 | 6), and
S(10 | 6)
Looking at Figure 5.30 we see that there are very few diﬀerences between
ESP1 and ESP6 which are lower than -0.10: we have 4, 9, and 7 patients
for S(7 | 6), S(8 | 6), and S(10 | 6), respectively. As happened before, those
patients showing high diﬀerences at year 7 and 8 do not coincide with those
showing high diﬀerences at year 10. For example, the four high DIFF16s at
year 7 tend to decrease with time, whereas those DIFF16s which which are
lower that -0.10 at year 10 where smaller at year 7 and 8. This behaviour
is strictly linked to the diﬀerent longitudinal trajectories. Patients with de-
creasing DIFF16s have longitudinal trajectories similar to those of patients
93 and 142, which are characterized by high covariate values, especially after
year 6. Since model J6 considers at year t the covariate values at year t−2,
ESP6 decrease more slowly than ESP1 with this type of trajectories. The
decrement of DIFF16 with time is mostly due to the low-ESP eﬀect. As
exampe, this time we consider patient 142. DIFF17 at year 7, 8, and 10 is
equal to -0.130, -0.152, and -0.004, respectively. Thus, it slowly increases
between year 7 and 8 and then decreases until year 10. In Figure 5.32 we
see that ESP1 decreases faster than ESP6. However, the ESP1 decrement
88rate is slowing after year 9 and this gives to ESP6 the opportunity to reach
ESP1 at year 10. Apart from the lower boundary issue, the same reasoning
is applicable when trajectories similar to those of patients 39 and 166 are
involved: since model J6 uses lagged covariate values, which are lower than
the current values, ESP6 decrease more slowly than ESP1 and this become
more evident at year 10 (see Figure 5.32).
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Figure 5.31: DIFF16 for S(7 | 6) [circle], S(8 | 6) [square], and S(10 | 6)
[triangle]
89S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP6 DIFF16 ESP1 ESP6 DIFF16 ESP1 ESP6 DIFF16
135 0.996 0.992 0.004 0.991 0.984 0.007 0.973 0.960 0.013
218 0.995 0.991 0.004 0.989 0.979 0.010 0.965 0.944 0.021
19 0.995 0.991 0.004 0.986 0.980 0.006 0.944 0.942 0.002
96 0.992 0.986 0.006 0.980 0.969 0.011 0.925 0.916 0.009
34 0.984 0.980 0.004 0.958 0.953 0.005 0.842 0.859 -0.017
48 0.980 0.970 0.010 0.950 0.935 0.015 0.838 0.836 0.002
136 0.975 0.966 0.009 0.938 0.924 0.014 0.809 0.797 0.012
99 0.975 0.967 0.008 0.935 0.926 0.009 0.767 0.804 -0.037
258 0.963 0.956 0.007 0.906 0.896 0.010 0.718 0.697 0.021
166 0.962 0.966 -0.004 0.881 0.918 -0.037 0.457 0.701 -0.244
39 0.951 0.965 -0.014 0.851 0.910 -0.059 0.470 0.671 -0.201
161 0.890 0.865 0.025 0.754 0.717 0.037 0.477 0.415 0.062
133 0.878 0.873 0.005 0.725 0.719 0.006 0.421 0.382 0.039
85 0.866 0.882 -0.016 0.659 0.734 -0.075 0.214 0.362 -0.148
180 0.789 0.791 -0.002 0.547 0.566 -0.019 0.174 0.172 0.002
104 0.755 0.849 -0.094 0.461 0.637 -0.176 0.114 0.199 -0.085
46 0.726 0.797 -0.071 0.378 0.546 -0.168 0.038 0.077 -0.039
142 0.617 0.747 -0.13 0.298 0.450 -0.152 0.066 0.071 -0.005
51 0.548 0.678 -0.13 0.235 0.356 -0.121 0.048 0.048 0
93 0.370 0.572 -0.202 0.095 0.233 -0.138 0.006 0.012 -0.006
Table 5.14: Comparison of ESP1, ESP6, and DIFF16 over time
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Figure 5.32: Comparison of ESP1 (ﬁrst column) and ESP6 (second column)
of two patients. The solid line depicts the mean of πi(u | t) over the Monte
Carlo samples. The dashed line depicts a 95% pointwise conﬁdence intervals
based on the quantiles of πi(u | t) over the Monte Carlo samples.
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Figure 5.33: Scatter plots of ESP1 and ESP7 for S(7 | 6), S(8 | 6), and
S(10 | 6)
Comparing Figure 5.20 with Figure 5.33 and Figure 5.21 with Figure
5.34 we see that the patterns are the same. However, comparing ESP7s with
ESP2s, we notice that model J7 is slightly more optimist or more pessimist
than model J2. Again, this behaviour is strictly linked to the patient’s lon-
gitudinal trajectory. Since model J7 uses lagged slope values, ESP7s are
higher than ESP2s if the current slope is increasing after year 6. In fact,
model J7 uses smaller slope values. On the contrary, if the current slope is
decreasing, ESP7 will be lower than ESP2 because ESP7 uses higher slope
values. Comparing the results in Table 5.15 and Table 5.10, we see that, in
the former case, DIFF17 tends to be bigger than DIFF12 (see, for instance,
patients 135, 96, 218, 46), whereas, in the latter case, it will be smaller (see,
for instance, patients 166, 133, 142, 51, 93).
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Figure 5.34: DIFF17 for S(7 | 6) [circle], S(8 | 6) [square], and S(10 | 6)
[triangle]
S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP7 DIFF17 ESP1 ESP7 DIFF17 ESP1 ESP7 DIFF17
135 0.996 0.979 0.017 0.991 0.948 0.043 0.973 0.839 0.134
218 0.995 0.970 0.025 0.989 0.921 0.068 0.965 0.745 0.220
19 0.995 0.971 0.024 0.986 0.924 0.062 0.944 0.744 0.200
96 0.992 0.967 0.025 0.980 0.913 0.067 0.925 0.721 0.204
34 0.984 0.948 0.036 0.958 0.873 0.085 0.842 0.658 0.184
48 0.980 0.974 0.006 0.950 0.936 0.014 0.838 0.809 0.029
136 0.975 0.956 0.019 0.938 0.895 0.043 0.809 0.728 0.081
99 0.975 0.963 0.012 0.935 0.910 0.025 0.767 0.750 0.017
258 0.963 0.930 0.033 0.906 0.839 0.067 0.718 0.625 0.093
166 0.962 0.932 0.030 0.881 0.794 0.087 0.457 0.381 0.076
39 0.951 0.846 0.105 0.851 0.661 0.190 0.470 0.346 0.124
161 0.890 0.955 -0.065 0.754 0.903 -0.149 0.477 0.783 -0.306
133 0.878 0.908 -0.030 0.725 0.810 -0.085 0.421 0.614 -0.193
85 0.866 0.930 -0.064 0.659 0.825 -0.166 0.214 0.560 -0.346
180 0.789 0.929 -0.140 0.547 0.833 -0.286 0.174 0.599 -0.425
104 0.755 0.735 0.020 0.461 0.521 -0.060 0.114 0.255 -0.141
46 0.726 0.854 -0.128 0.378 0.637 -0.259 0.038 0.208 -0.170
142 0.617 0.695 -0.078 0.298 0.480 -0.182 0.066 0.254 -0.188
51 0.548 0.643 -0.095 0.235 0.441 -0.206 0.048 0.251 -0.203
93 0.370 0.666 -0.296 0.095 0.431 -0.336 0.006 0.194 -0.188
Table 5.15: Comparison of ESP1, ESP7, and DIFF17 over time
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Figure 5.35: Scatter plots of ESP1 and ESP8 for S(7 | 6), S(8 | 6), and
S(10 | 6)
Also in this case, as already happened in the comparison between ESP1s
and ESP3s, model J8 give results which are very close to those of model J1
(see Figure 5.35). We report Figure 5.36 and Table 5.16 for completeness.
S(7 | 6) S(8 | 6) S(10 | 6)
Patient ESP1 ESP8 DIFF18 ESP1 ESP8 DIFF18 ESP1 ESP8 DIFF18
135 0.996 0.996 0 0.991 0.991 0 0.973 0.970 0.003
218 0.995 0.994 0.001 0.989 0.986 0.003 0.965 0.949 0.016
19 0.995 0.995 0 0.986 0.986 0 0.944 0.936 0.008
96 0.992 0.991 0.001 0.980 0.974 0.006 0.925 0.884 0.041
34 0.984 0.982 0.002 0.958 0.948 0.010 0.842 0.771 0.071
48 0.980 0.983 -0.003 0.950 0.958 -0.008 0.838 0.870 -0.032
136 0.975 0.974 0.001 0.938 0.934 0.004 0.809 0.785 0.024
99 0.975 0.979 -0.004 0.935 0.946 -0.011 0.767 0.803 -0.036
258 0.963 0.962 0.001 0.906 0.900 0.006 0.718 0.675 0.043
166 0.962 0.968 -0.006 0.881 0.900 -0.019 0.457 0.494 -0.037
39 0.951 0.943 0.008 0.851 0.832 0.019 0.470 0.415 0.055
161 0.890 0.902 -0.012 0.754 0.782 -0.028 0.477 0.513 -0.036
133 0.878 0.883 -0.005 0.725 0.741 -0.016 0.421 0.438 -0.017
85 0.866 0.893 -0.027 0.659 0.728 -0.069 0.214 0.308 -0.094
180 0.789 0.830 -0.041 0.547 0.600 -0.053 0.174 0.198 -0.024
104 0.755 0.758 -0.003 0.461 0.489 -0.028 0.114 0.146 -0.032
46 0.726 0.786 -0.060 0.378 0.465 -0.087 0.038 0.039 -0.001
142 0.617 0.584 0.033 0.298 0.271 0.027 0.066 0.058 0.008
51 0.548 0.532 0.016 0.235 0.246 -0.011 0.048 0.064 -0.016
93 0.370 0.437 -0.067 0.095 0.152 -0.057 0.006 0.023 -0.017
Table 5.16: Comparison of ESP1, ESP8, and DIFF18 over time
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95Conclusions
Longitudinal studies, such as clinical trials or observational studies, often pro-
duce two types of outcome: one or more repeatedly measured biomarkers,
along with baseline covariates, and the elapsed time to an event of interest.
These markers are frequently important heath indicators since they can be
used to monitor the disease progression. In order to optimally use the infor-
mation contained in the collected data and signiﬁcantly reduce the bias due
to the traditional separate analyses of these types of data, a joint modeling
approach has been recently proposed and is currently under development.
In this approach, the longitudinal process and the time-to-event process are
modeled simultaneously.
During the last decade, there has been an increasing interest in the use of
joint models to obtain subject-speciﬁc predictions for the survival outcome.
Survival predictions based on a joint model have the advantage that they
can be updated as soon as new information is available.
The association structure represents the way the longitudinal outcome is
related to the risk for an event. In the standard joint model, it is usually
assumed that the risk for an event at a particular time point t depends on the
current value of the longitudinal biomarker. However, this type of association
may not always be the most appropriate in expressing the correct relationship
between the longitudinal and the survival processes so that other types of
association structures should be considered. In fact, choosing one association
structure instead of another may substantially inﬂuence the derived results.
The aim of this work was indeed to investigate how sensitive are survival
97predictions with respect to the assumed association structure of the survival
sub-model. Seven where the alternative association structures considered in
this work which were formalized through seven diﬀerent parameterizations.
Our analysis was based on data collected during a study on primary
biliary cirrhosis (PBC). The serum bilirubin level is the longitudinal covariate
considered while death is the event of interest. After having estimated the
eight joint models, for each of them, we computed the patients’ expected
survival probabilities (ESPs) at diﬀerent time points. We remind that the
expected survival probability of a patient is the estimate of the conditional
probability of surviving time u > t given survival up to t, i.e. S(t + ∆t | t).
Subsequently, we compare the ESPs of the standard model with those of the
alternative models.
Not surprisingly, those parameterizations which were more similar to the
standard one were more likely to give analogous ESPs. However, indepen-
dently of the alternative parameterization used, the diﬀerences between ESPs
where more accentuate for the high risk patients. Their longitudinal tra-
jectories, in fact, are characterized by high serum bilirubin values and an
increasing trend (i.e. positive slope) which may be more or less pronounced.
With this type of trajectories, in comparison with the standard parameter-
ization, the diﬀerent interpretation of the trajectory features given by the
alternative parameterizations shows its maximum eﬀect. On the contrary,
the discrepancies between ESPs of low risk patients are usually small. In
fact, their longitudinal trajectories are characterized by small serum bilirubin
values, especially at the beginning of the study, which tend to stay constant
or slightly increase over time. These trajectory features guarantee similar
ESPs. Thus, in general, for low risk patients, using one association structure
instead of another does not have a strong inﬂuence on the obtained ESPs.
On the contrary, for high risk patients the choice of the association structure
has a much stronger impact.
Furthermore, in this type of analysis, the evolution in time of the lon-
gitudinal covariate should not be forgotten. In fact, the ESPs comparisons
98have been done considering diﬀerent values for both t and ∆t. In particular,
the most interesting results were found keeping t ﬁxed while increasing the
prediction interval ∆t. In our analysis we have chosen ∆t = 1,2,4 years.
The fact that for ∆t = 1, the standard parameterization and an alternative
one give similar or, on the contrary, very diﬀerent ESPs does not guarantee
that it will be the same for ∆t = 2 or ∆t = 4. Diﬀerences can either stay
constant or increase or decrease when ∆t increases. Again, everything de-
pends on the evolution of the patient’s longitudinal trajectory whose features
are diﬀerently interpreted by the eight considered models.
Besides, monitoring the value of the diﬀerences between ESPs as ∆t in-
creases, we noticed that, for high-risk patients, it was decreasing. We called
this phenomenon the low-ESP eﬀect. In comparison with the other alter-
native parameterizations, the standard parameterization tends to be more
pessimist with high risk patients. This means that, for these patients, the
ESPs of the standard joint model have a higher decreasing rate so that they
already reach values close to zero when ∆t = 2. Since zero is the lower bound-
ary, the ESP of the standard joint model will not signiﬁcantly decrease any
further while the ESP of the alternative model, being much higher when
∆t = 2, will still have space to decrease. Thus, as ∆t augments, the two
ESP values will become closer.
We are aware of the fact that our work may be questionable since the
diﬀerences in ESPs are not only due to the assumed association structure
but also to the fact that each model has its own estimates of the parameters
deﬁning the longitudinal sub-model and the baseline hazard function of the
survival sub-model. However, it can easily be noticed that it is the association
structure to have the greatest inﬂuence on the computation of the ESPs. If
this wasn’t true, we would not have individuate the strong link between the
ESPs and the features of the longitudinal trajectory.
We believe that joint models, thanks to their capability to maximize the
use of the information contained in prognostic factors such as biomarkers, will
constitute a precious tool in the future clinical practice. The physician expe-
99rience combined with a subject-speciﬁc survival probability would hopefully
help decision making and improve clinical outcome. Due to their important
application in patients’ management, it is important to obtain survival prob-
abilities which are as accurate as possible. Our analysis has demonstrated
how strong can be the inﬂuence of the assumed association structure on
individual expected survival probabilities, especially for high risk patients.
Therefore, in the part of the data analysis dedicated to the choice of the more
appropriate prognostic model, it is fundamental to consider and investigate
alternative associations between the longitudinal covariate and the risk for
an event and not solely rely on the standard one. The availability of statis-
tical softwares within the joint modeling framework has recently made this
investigation rather feasible.
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